



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07B 53/00, C07C 43/196, C07F 7/18, C07C 41/26, C12P 41/00	A1	(11) International Publication Number: WO 96/30320 (43) International Publication Date: 3 October 1996 (03.10.96)
(21) International Application Number: PCT/US96/02801 (22) International Filing Date: 1 March 1996 (01.03.96) (30) Priority Data: 08/411,136 27 March 1995 (27.03.95) US 08/588,584 1 February 1996 (01.02.96) US (71) Applicant: HOECHST MARION ROUSSEL, INC. [US/US]; 2110 East Galbraith Road, P.O. Box 156300, Cincinnati, OH 45215-6300 (US). (72) Inventors: CURRAN, Timothy, T.; Apartment 1B, 9215 Deer- cross Parkway, Cincinnati, OH 45236 (US). HAY, David, A.; 9464 Hadway Drive, Indianapolis, IN 46256 (US). EVANS, Jonathan, C.; 4616 Congress Drive, Midland, MI 48642 (US). (74) Agent: LENTZ, Nelsen, L.; Hoechst Marion Roussel, Inc., 2110 East Galbraith Road, P.O. Box 156300, Cincinnati, OH 45215-6300 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: PREPARATION OF CIS-4-O-PROTECTED-2-CYCLOPENTENOL DERIVATIVES		
(57) Abstract The present invention relates to a novel process for preparing cis-4-O-protected-substituted-2-cyclopentenol derivatives comprising, (a) dissolving a 4-O-protected-2-cyclopentenone in a suitable organic solvent; and (b) treating the solution with a suitable Lewis acid and a suitable reducing agent at a temperature of from about -100 °C to about 20 °C. The cis-4-O-protected-substituted-2-cyclopentenol derivatives are useful intermediates in the preparation of various cyclopentanyl and cyclopentenyl purine analogs which are useful as immunosuppressants and in the preparation of various prostaglandins.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam


5 PREPARATION OF CIS-4-O-PROTECTED-2-CYCLOPENTENOL
DERIVATIVES

BACKGROUND OF THE INVENTION

10 The present invention relates to a novel process for
preparing cis-4-O-protected-2-cyclopentenol derivatives
which are useful intermediates in the preparation of
various cyclopentanyl and cyclopentenyl purine analogs
which are useful as immunosuppressants as disclosed by
15 Borcherding, et al. in European Patent Application
Publication Nos. 0 475 411 A1, published March 18, 1992, 0
475 413 A2, published March 18, 1992, and 0 545 413 A1,
published June 9, 1993. In addition, cis-4-O-protected-2-
cyclopentenol derivatives are useful intermediates in the
20 preparation of various prostaglandins.

SUMMARY OF THE INVENTION

The present invention provides a novel process for the
25 preparation of a CIS compound of the formula (II):




formula (II)

30 wherein Pg is selected from the group consisting of benzyl, substituted benzyl, $-\text{CH}_2\text{OCH}_3$, $-\text{CH}_2\text{SCH}_3$, $-\text{CH}_2\text{OCH}_2\text{phenyl}$, $-\text{CH}_2\text{OCH}_2\text{CH}_2\text{OCH}_3$, $-\text{CH}_2\text{OCH}_2\text{CCl}_3$, $-\text{CH}(\text{OCH}_2\text{CH}_2\text{Cl})_2$, $-\text{CH}_2\text{OCH}_2\text{CH}_2\text{Si}(\text{CH}_3)_3$, $-\text{CH}(\text{OC}_2\text{H}_5)\text{CH}_3$, $-\text{C}(\text{OCH}_3)(\text{CH}_3)_2$,
35 $-\text{CH}(\text{CH}_3)\text{OCH}(\text{CH}_3)_2$, $-\text{CH}_2\text{CCl}_3$, $-\text{C}(\text{CH}_3)_3$, $-\text{CH}_2\text{CH}=\text{CH}_2$, $-\text{CH}_2\text{CH}=\text{CHphenyl}$, $-\text{CH}(\text{phenyl})_2$, $-\text{C}(\text{phenyl})_3$, tetrahydropyranyl, 4-methoxytetrahydropyranyl, 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl, tetrahydrofuranyl,

2
tetrahydrothiofuranyl, and $\text{SiR}_1\text{R}_2\text{R}_3$, wherein R_1 , R_2 and R_3
are each independently C_1 - C_4 alkyl, phenyl, benzyl,
substituted phenyl or substituted benzyl, comprising;

- 5 a) dissolving a compound of the formula (I)



formula (I)


10

wherein Pg is defined as above, in a suitable organic
solvent; and

- b) treating the solution with a suitable Lewis acid
and a suitable reducing agent at a temperature of from
15 about -100°C to about 20°C .

The present invention further provides a novel process
for the preparation of the CIS enantiomer of the formula
(IIa):

20




formula (IIa)

- 25 wherein Pg is selected from the group consisting of benzyl,
substituted benzyl, $-\text{CH}_2\text{OCH}_3$, $-\text{CH}_2\text{SCH}_3$, $-\text{CH}_2\text{OCH}_2\text{phenyl}$,
 $-\text{CH}_2\text{OCH}_2\text{CH}_2\text{OCH}_3$, $-\text{CH}_2\text{OCH}_2\text{CCl}_3$, $-\text{CH}(\text{OCH}_2\text{CH}_2\text{Cl})_2$,
 $-\text{CH}_2\text{OCH}_2\text{CH}_2\text{Si}(\text{CH}_3)_3$, $-\text{CH}(\text{OC}_2\text{H}_5)\text{CH}_3$, $-\text{C}(\text{OCH}_3)(\text{CH}_3)_2$,
 $-\text{CH}(\text{CH}_3)\text{OCH}(\text{CH}_3)_2$, $-\text{CH}_2\text{CCl}_3$, $-\text{C}(\text{CH}_3)_3$, $-\text{CH}_2\text{CH}=\text{CH}_2$,
30 $-\text{CH}_2\text{CH}=\text{CHphenyl}$, $-\text{CH}(\text{phenyl})_2$, $-\text{C}(\text{phenyl})_3$,
tetrahydropyranyl, 4-methoxytetrahydropyranyl,
3-bromotetrahydropyranyl, tetrahydrothiopyranyl,
4-methoxytetrahydrothiopyranyl, tetrahydrofuranyl,
tetrahydrothiofuranyl, and $\text{SiR}_1\text{R}_2\text{R}_3$, wherein R_1 , R_2 and R_3
are each independently C_1 - C_4 alkyl, phenyl, benzyl,
35 substituted phenyl or substituted benzyl, comprising;

3

- a) dissolving an enantiomeric compound of the formula (Ia)

5



formula (Ia)

wherein Pg is defined as above, in a suitable organic solvent; and


10

- b) treating the solution with a suitable Lewis acid and a suitable reducing agent at a temperature of from about -100°C to about 20°C .

15

In addition, the present invention provides a novel process for the preparation of the CIS enantiomer of the formula (IIb):

20




formula (IIb)

wherein Pg is selected from the group consisting of benzyl, substituted benzyl, $-\text{CH}_2\text{OCH}_3$, $-\text{CH}_2\text{SCH}_3$, $-\text{CH}_2\text{OCH}_2\text{phenyl}$, $-\text{CH}_2\text{OCH}_2\text{CH}_2\text{OCH}_3$, $-\text{OCH}_2\text{OCH}_2\text{CCl}_3$, $-\text{CH}(\text{OCH}_2\text{CH}_2\text{Cl})_2$, $-\text{CH}_2\text{OCH}_2\text{CH}_2\text{Si}(\text{CH}_3)_3$, $-\text{CH}(\text{OC}_2\text{H}_5)\text{CH}_3$, $-\text{C}(\text{OCH}_3)(\text{CH}_3)_2$, $-\text{CH}(\text{CH}_3)\text{OCH}(\text{CH}_3)_2$, $-\text{CH}_2\text{CCl}_3$, $-\text{C}(\text{CH}_3)_3$, $-\text{CH}_2\text{CH}=\text{CH}_2$, $-\text{CH}_2\text{CH}=\text{CHphenyl}$, $-\text{CH}(\text{phenyl})_2$, $-\text{C}(\text{phenyl})_3$, tetrahydropyranyl, 4-methoxytetrahydropyranyl, 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl, tetrahydrofuranlyl, tetrahydrothiofuranlyl, and $\text{SiR}_1\text{R}_2\text{R}_3$, wherein R_1 , R_2 and R_3 are each independently C_1 - C_4 alkyl, phenyl, benzyl, substituted phenyl or substituted benzyl, comprising;

35

a) dissolving an enantiomeric compound of the formula⁴
(Ib)

5



formula (Ib)

wherein Pg is defined as above, in a suitable organic
solvent; and


10

b) treating the solution with a suitable Lewis acid
and a suitable reducing agent at a temperature of from
about -100°C to about 20°C.

15


In addition, the present invention further provides a
novel process for the preparation of the CIS compounds of
the formulas (IIb) and (IV):

20



formula (IIb)

25



formula (IV)


wherein Z is C₂-C₄ alkanoyl; and Pg is selected from the
group consisting of benzyl, substituted benzyl, -CH₂OCH₃,
-CH₂SCH₃, -CH₂OCH₂phenyl, -CH₂OCH₂CH₂OCH₃, -CH₂OCH₂CCl₃,
-CH(OCH₂CH₂Cl)₂, -CH₂OCH₂CH₂Si(CH₃)₃, -CH(OC₂H₅)CH₃,
-C(OCH₃)(CH₃)₂, -CH(CH₃)OCH(CH₃)₂, -CH₂CCl₃, -C(CH₃)₃,
-CH₂CH=CH₂, -CH₂CH=CHphenyl, -CH(phenyl)₂,
tetrahydropyranyl, 4-methoxytetrahydropyranyl,
3-bromotetrahydropyranyl, tetrahydrothiopyranyl,
4-methoxytetrahydrothiopyranyl, tetrahydrofuranyl,
tetrahydrothiofuranyl, and SiR₁R₂R₃, wherein R₁, R₂ and R₃

30

35


are each independently C₁-C₄ alkyl, phenyl, benzyl, substituted phenyl or substituted benzyl, comprising;

a) dissolving a compound of the formula (I)



10 wherein Pg is defined as above, in a suitable organic solvent;

b) treating the solution with a suitable Lewis acid and a suitable reducing agent at a temperature of from about -100°C to about 20°C to yield the CIS compound of formula (II);



20 wherein Pg is as defined above;


c) treating the CIS compound of formula (II) with a suitable enzyme and an excess of a suitable acylating agent, in a suitable solvent to yield a mixture of compounds of the formulas (IIb) and (IV), as defined above; and

d) separating the compound of formula (IIb) from compound of formula (IV).


30 The invention further provides a novel process for the preparation of a CIS compound of formulas (II), (IIa), (IIb) or (IV), as defined above, wherein a suitable alcohol is added to the reaction mixture concomitantly with or prior to treating the compound of formula (I) with the suitable reducing agent.

35

The invention further provides a novel process for the preparation of the CIS compounds of the formulas (VIb) and (VII):




formula (VIb)



formula (VII)

wherein Z is C₂-C₄ alkanoyl; and Pg is selected from the group consisting of benzyl, substituted benzyl, -CH₂OCH₃, -CH₂SCH₃, -CH₂OCH₂phenyl, -CH₂OCH₂CH₂OCH₃, -CH₂OCH₂CCl₃, -CH(OCH₂CH₂Cl)₂, -CH₂OCH₂CH₂Si(CH₃)₃, -CH(OC₂H₅)CH₃, -C(OCH₃)(CH₃)₂, -CH(CH₃)OCH(CH₃)₂, -CH₂CCl₃, -C(CH₃)₃, -CH₂CH=CH₂, -CH₂CH=CHphenyl, -CH(phenyl)₂, tetrahydropyranyl, 4-methoxytetrahydropyranyl, 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl, tetrahydrofuranyl, tetrahydrothiofuranyl, and SiR₁R₂R₃, wherein R₁, R₂ and R₃ are each independently C₁-C₄ alkyl, phenyl, benzyl, substituted phenyl or substituted benzyl, comprising treating the CIS compound of formula (VI);



formula (VI)

wherein Pg is as defined above, with a suitable enzyme and an excess of a suitable acylating agent in a suitable solvent, to yield a mixture of compounds of the formulas (VIb) and (VII), as defined above; and

f) separating the compound of formula (VIb) from the compound of formula (VII).

7
DETAILED DESCRIPTION OF THE INVENTION

5 The term "stereoisomers" is a general term for all isomers of individual molecules that differ only in the orientation of their atoms in space. It includes geometric (*cis/trans*) isomers, and isomers of compounds with more than one asymmetric center that are not mirror images of one
10 another (diastereomers). The terms "enantiomer" or "enantiomeric" refers to a molecule that is nonsuperimposable on its mirror image and hence optically active wherein the enantiomer rotates the plane of polarized light in one direction and its mirror image
15 rotates the plane of polarized light in the opposite direction. The terms "racemic mixture" or "racemic modification" refer to a mixture of equal parts of enantiomers. A racemic modification or racemic mixture are optically inactive. As used herein the prefixes "(+)" and
20 "(-)" are employed to designate the sign of rotation of plane polarized light by the compound, with (+) meaning the compound is dextrorotatory and (-) meaning the compound is levorotatory.

25 The term "enantiomeric enrichment" refers to the increase in the amount of one enantiomer as compared to the other enantiomer. A convenient method of expressing enantiomeric enrichment achieved is the concept of "enantiomeric excess" or "ee", which is expressed by the
30 following equation;


$$ee = \frac{E^1 - E^2}{E^1 + E^2} \times 100$$

35 in which E^1 is the amount of the first enantiomer and E^2 is the amount of the second corresponding enantiomer. For example, where the initial ratio of two enantiomers in a reaction is 50:50 (a racemic mixture) and the reaction

8

produces enantiomeric enrichment with a final ratio of 90:10, then the ee with respect to the first enantiomer is 80%. It is preferred that ee's of greater than 90% be obtained.

It is understood that the enantiomers of formula (IIa) and the corresponding enantiomers of formula (IIb) are mirror images of each other. It is further understood that the enantiomers of formulas (IIa) and (IIb) are also in the CIS configuration. In addition, the CIS compounds of formula (II) are racemic mixtures of the corresponding enantiomers of formulas (IIa) and (IIb). It is also further understood that the enantiomeric compounds of formula (Ia) and the corresponding enantiomeric compounds of formula (Ib) are mirror images of each other. For example the enantiomer of formula (Ia') and the enantiomer of formula (Ib') below are mirror images of each other.



25

As used herein the term "C₁-C₄ alkyl" refers to a saturated straight or branched chain hydrocarbon radical of one to four carbon atoms. Included within the scope of this term are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and the like.

30

As used herein the term "C₂-C₄ alkanoyl" refers to an acetyl, propionyl and butyryl group.

35

As used herein the term "C₁-C₄ alkoxy" refers to a straight or branched alkoxy group containing from 1-4 carbon atoms and includes methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, t-butoxy, and the like.


9

As used herein the term "halogen", "halo", "halide", or
"hal" refers to fluorine atom, chlorine atom, bromine atom,
5 or iodine atom.


The term "TBDMS" refers to a tert-butyldimethylsilyl
functionality of the formula:




The term "phenyl" refers the phenyl functionality of
15 the formula:



The terms "benzyl" or "Bn" refers the benzyl
20 functionality of the formula:



The term "substituted phenyl" refers the substituted
25 phenyl functionality of the formula:



wherein R is C₁-C₄ alkyl, C₁-C₄ alkoxy, NO₂, -CN, F, Cl, Br
30 or I, which can be located at the ortho, meta or para
position on the ring.

The term "substituted benzyl" refers the substituted
benzyl functionality of the formula:




10
wherein R is C₁-C₄ alkyl, C₁-C₄ alkoxy; NO₂, -CN, F, Cl, Br or I, which can be located at the ortho, meta or para position on the ring.

5




The term "THP" refers the tetrahydro-pyran-2-yl functionality of the formula:

10




The terms "acetyl", "propionyl" and "butyryl" refer the following functional groups respectively:

15



20

As used herein a CIS compound such as compound A



25

means the hydrogens at positions 1 and 2 on the cyclopentenyl ring are both on the same plane of the ring and the substituents OH and OJ, wherein J is H or Pg, at positions 1 and 2, are also on the same plane of the ring as each other. Thus, OH and OJ are in the plane opposite the hydrogens at positions 1 and 2.

30

35

11

The designation "  " refers to a bond that protrudes forward out of the plane of the page.

5

The designation "  " refers to a bond that protrudes backward out of the plane of the page.

10

The designation "  " refers to a bond for which the stereochemistry is not designated.

United States Patent Application Serial Number
15 08/411,136 filed March 27, 1995, entitled "PREPARATION OF
CIS-4-O-PROTECTED-2-CYCLOPENTENOL DERIVATIVES" is hereby
incorporated by reference.


20 Scheme I describes the preparation of compounds of
formulas (I), (II) and (III). All the substituents, unless
otherwise indicated, are previously defined. The reagents
and starting materials are readily available to one of
ordinary skill in the art.

25

30

35

12
Scheme I



In step a, the 4-hydroxy-2-cyclopentenone (2) is readily prepared from furfuryl alcohol (1) by one of ordinary skill in the art following the procedure described by Masayoshi Nanni, Harima Ta-machi and Moriyama-shi,

Japanese Patent Disclosure Bulletin, KOKAI No. 57-62236, April 15, 1982, or alternatively as described by G, Piancatelli et al., Tetrahedron, 34, 2775 (1978).

- 5 In step b, 4-hydroxy-2-cyclopentenone (2) is protected with a suitable protecting group to provide the compound of formula (I) utilizing techniques and procedures well known to one of ordinary skill in the art. Examples of suitable protecting groups are described by T.W. Greene,
- 10 "Protective Groups in Organic Synthesis", John Wiley & Sons, Inc., 1981, Chapter 2, such as methoxymethyl, methylthiomethyl, benzyloxymethyl, 2-methoxyethoxymethyl, 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl, tetrahydropyranyl, 3-
- 15 bromotetrahydropyranyl, tetrahydrothiopyranyl, 4-methoxytetrahydropyranyl, 4-methoxytetrahydrothiopyranyl, tetrahydrofuranyl, tetrahydrothiofuranyl, 1-ethoxyethyl, 1-methyl-1-methoxyethyl, 2,2,2-trichloroethyl, tert-butyl, allyl, cinnamyl, p-chlorophenyl, benzyl, p-methoxybenzyl,
- 20 o-nitrobenzyl, p-nitrobenzyl, p-chlorobenzyl, p-bromobenzyl, p-cyanobenzyl, diphenylmethyl, triphenylmethyl, triethylsilyl, triisopropylsilyl, isopropyl dimethylsilyl, tert-butyl dimethylsilyl, methyl diethylsilyl, dimethylethylsilyl, methyl diisopropylsilyl, methyl-di-
- 25 tert-butylsilyl, tribenzylsilyl, triphenylsilyl, phenyl dimethylsilyl, benzyl methylethylsilyl, phenylethyl methylsilyl, tri-o-tolylsilyl, tert-butyl diphenylsilyl and the like. The preferred suitable protecting groups are tetrahydropyranyl and tert-
- 30 butyl dimethylsilyl. The most preferred suitable protecting groups are tert-butyl dimethylsilyl and trityl. The compounds of formula (I) are readily prepared by one of ordinary skill utilizing generally the procedures described by T.W. Greene, "Protective Groups in Organic Synthesis",
- 35 John Wiley & Sons, Inc., 1981, Chapter 2. For example, the protection step can be carried out by dissolving the 4-hydroxy-2-cyclopentenone (2) in an inert, substantially anhydrous, organic solvent in the presence of an acid

14

acceptor, preferably a nitrogen base such as triethylamine, quinoline, lutidine, imidazole or pyridine. The preferred acid acceptor is triethylamine. Examples of suitable solvents for the protection step are methylene chloride, tetrahydrofuran, chloroform, tetrachloroethane, nitromethane, benzene, diethyl ether, acetonitrile, dimethylformamide and the like. The preferred suitable solvent is tetrahydrofuran. A catalytic amount of 4-dimethylaminopyridine (DMAP) may optionally be added to the solution. The solution is then cooled to about 0°C and approximately one equivalent of a suitable silylating agent is added to the solution. The reaction is allowed to stir for 2 to 14 hours and then the compound of formula (I) is isolated and purified by techniques well known in the art, such as extractive methods and distillation. For example, the reaction is poured into aqueous 0.5N hydrochloric acid and the phases separated. The aqueous phase is extracted with a suitable organic solvent, such as heptane. The organic extract is combined with the organic phase and rinsed with 5% sodium bicarbonate, brine, dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum. The residue can then be purified by Kugelrohr distillation to provide the compound of formula (I).

In step c, the compound of formula (I) is selectively reduced to provide the CIS compound of formula (II). For example, the compound of formula (I) and a suitable Lewis acid are dissolved in a suitable organic solvent under an inert atmosphere, such as argon, with stirring. The suitable organic solvent is essentially anhydrous and may be a mixture of suitable organic solvents or a single organic solvent. Examples of a suitable organic solvent are diethyl ether, dipropyl ether, tert-butyl methyl ether, toluene/tert-butyl methyl ether, heptane/tert-butyl methyl ether, toluene/diethyl ether and the like. The preferred suitable organic solvents are diethyl ether,

15

toluene/diethyl ether or toluene/tert-butyl methyl ether. The most preferred suitable organic solvents are toluene/diethyl ether or toluene/tert-butyl methyl ether.

5 The amount of suitable Lewis acid utilized is from about 0.10 eq to about 5 eq with about 0.5 eq being preferred. Examples of a suitable Lewis acid are lithium chloride, lithium bromide, lithium iodide, lithium perchlorate, zinc chloride, magnesium bromide, cerium(III) chloride and the

10 like. The preferred suitable Lewis acids are lithium iodide and lithium bromide, with lithium iodide being the most preferred suitable Lewis acid. The temperature of the solution required for the selective reduction is from about -100°C to about 20°C. The preferred temperature is from

15 about -78°C to about -10°C with about -25°C being the most preferred temperature of the solution. The solution is then treated with a suitable reducing agent. The preferred amount of suitable reducing agent utilized is from about 0.4 eq to about 5 eq, with about 0.5 eq being most

20 preferred. Examples of suitable reducing agents are lithium aluminum hydride, lithium trimethoxyaluminumhydride, REDAL® (Aldrich Chemical Company, Milwaukee, Wisconsin), lithium borohydride and the like. The preferred suitable reducing agent is lithium

25 aluminum hydride. After addition of the suitable reducing agent, the reaction is stirred for about 1 hour to about 5 hours, with about 2 hours being preferred. The reaction is then cautiously quenched and the product isolated and purified utilizing conditions well known in the art. For

30 example, approximately 1 to 2 eq of aqueous sodium hydroxide (1N) is added at a rate that maintains the temperature of the reaction below 20°C. After the reaction is quenched, it is filtered through a pad of diatomaceous earth, such as CELITE, (available from Aldrich Chemical

35 Company, Milwaukee, Wisconsin). The pad of diatomaceous earth is then rinsed with a suitable organic solvent, such as toluene. The filtrate is separated and the aqueous phase is extracted with a suitable solvent, such as

16

toluene. The organic phases can be combined and washed sequentially with aqueous sodium hydroxide (1N), brine, dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum to provide the compound of formula (II), which can be purified by techniques well known in the art, such as chromatography or distillation. Gas chromatography (GC) can be utilized by one of ordinary skill in the art to determine the ratio of CIS compound of formula (II) to the by-products of the reduction, which are compounds 2 and 3.

In addition, in step c, the compound of formula (I) can be selectively reduced to provide the CIS compound of formula (II) by addition of a suitable alcohol to the reaction mixture described above, under conditions analogous to those described hereinabove, either in the presence of the suitable Lewis acid, or alternatively, without addition of the suitable Lewis acid. Examples of suitable alcohols are isopropanol, 2-methyl-1-propanol, 2-methyl-2-butanol, 2-methyl-1-butanol, 3-methyl-1-butanol, 3-methyl-2-butanol, triethylsilanol, tert-butyldimethylsilanol, methyldiisopropylsilanol, isopropyldimethylsilanol, triisopropylsilanol, methyl-di-tert-butyldiphenylsilanol, triphenylsilanol, tert-butyldiphenylsilanol, phenyldimethylsilanol, benzylmethylethylsilanol, phenylmethylethylsilanol, tri-*o*-tolylsilanol, phenol and the like. The preferred suitable alcohols are isopropanol and tert-butyldimethylsilanol with tert-butyldimethylsilanol being most preferred. The amount of alcohol added can range from about 0 mol% to about 100 mol%. The preferred amount of alcohol added is about 16 mol% to about 30 mol% with about 20 mol% being most preferred. More specifically, for example, a suitable reducing agent, such as lithium aluminum hydride is combined with a suitable Lewis acid, such as lithium iodide in a suitable organic solvent, such as toluene. The reaction mixture is cooled to about -40°C to about -20°C and

17

a mixture of a compound of formula (I), such as 4-tert-butyltrimethylsiloxy-3-cyclopentanone, tert-butyltrimethylsilanol and tert-butyl methyl ether is added slowly to the reaction mixture. After stirring for about 5 hours the reaction is quenched with aqueous ammonium chloride and the product isolated and purified by techniques well known in the art, such as column chromatography on silica gel or by vacuum distillation.

10

It is understood by one of ordinary skill in the art that the reagents may be combined in various manners so long as the suitable alcohol is present when the suitable reducing agent is combined with the compound of formula (I). For example, the suitable Lewis acid can be combined with the suitable reducing agent and suitable alcohol in a suitable organic solvent, such as toluene. The reaction mixture is then treated with a solution of a compound of formula (I) in a suitable organic solvent, such as tert-butyl methyl ether to provide the CIS compound of formula (II). In another example, the suitable Lewis acid can be combined with the suitable reducing agent, a suitable alcohol in a suitable organic solvent, such as toluene, and a compound of formula (I) followed by addition of a suitable organic solvent, such as tert-butyl methyl ether to provide the CIS compound of formula (II).

In step d, the CIS compound of formula (II) is deprotected under conditions well known in the art to provide the CIS compound of formula (III) [see for example T.W. Greene, "Protective Groups in Organic Synthesis", John Wiley & Sons, Inc., 1981, Chapter 2]. For example, the compound of formula (II), wherein Pg is a trialkylsilyl protecting group, such as a tert-butyldimethylsilyl group, is dissolved in a suitable organic solvent, such as tetrahydrofuran. It is then optionally treated with approximately 0.15 eq of a suitable amine, such as triethylamine followed by treatment with approximately 1.1

18

eq of tetrabutylammonium fluoride (as a 1N solution in tetrahydrofuran) at room temperature. The reaction is stirred for about 2 to 6 hours and then the product is isolated and purified by techniques well known in the art. For example, the reaction is concentrated under vacuum and the residue purified by flash chromatography on silica gel with a suitable eluent, such as 10% acetone/ethyl acetate. The purified material is then recrystallized from a suitable organic solvent, such as chloroform to provide cis-2-cyclopentenyl-1,4-diol of formula (III).

In addition, in step d, the compound of formula (II) wherein Pg is a tetrahydro-pyran-2-yl group is dissolved in a suitable organic solvent, such as methanol or ethanol, and treated with a suitable acid, such as pyridinium p-toluenesulfonate (PPTS), at room temperature for 1 to 4 hours. The product is isolated and purified by techniques well known in the art. For example, the reaction is neutralized with a suitable base, such as sodium bicarbonate and concentrated under vacuum. The residue is then purified by flash chromatography on silica gel with a suitable eluent, such as 10% acetone/ethyl acetate. The purified material is then recrystallized from a suitable organic solvent, such as chloroform to provide cis-2-cyclopentenyl-1,4-diol of formula (III).

In a manner analogous to that described in Scheme I, compounds of formulas (IIa) and (IIb) can be prepared from the corresponding compounds of formulas (Ia) and (Ib). The compounds of formulas (Ia) and (Ib) can be prepared by one of ordinary skill in the art, for example following generally the procedure described by M. Asami, Tetrahedron Letters, 26(47), 5803-5806 (1985) or S.P. Khanapure et al., J. Org. Chem., 60, 7548-7551 (1995). In addition, the compounds of formulas (Ia) and (Ib) can be prepared by one of ordinary skill in the art from the compounds of formulas (IIb) and (IV) prepared in Scheme II shown below.

19

Scheme II describes the preparation of compounds of formulas (IIb) and (IV) from compounds of formula (II).

5 Compounds of formula (II) can be prepared following the procedure set forth in Scheme I. In addition, compounds of formula (II) can be prepared by converting cyclopentadiene to cis-2-cyclopentenyl-1,4-diol following the procedure described by Kaneko, C., et al., Synthesis, 876, (1974),
10 and then monoprotecting the diol with a suitable protecting group under conditions well known to one of ordinary skill in the art, for example as described by Jain, S., et al., Chemistry and Industry, 17, 576, (Sept. 1990), Rapoport, H. and Castello, A., J. Org. Chem., 51, 1006 (1986), McDougal, P., et al., J. Org. Chem., 51, 3388 (1986) and Roush, et al., J. Org. Chem., 56, 1636 (1991). All the
15 substituents, unless otherwise indicated, are previously defined. The reagents and starting materials are readily available to one of ordinary skill in the art.


20

25

30

35

20
Scheme II



In Scheme II, step A, a compound of formula (II) is subjected to an enzyme catalyzed enantioselective acylation

21

reaction under analogous conditions well known in the art, such as that described by Johnson, C.R., et al., Tetrahedron Letters, 35(12), 1833-1834 (1994), C.R.

- 5 Johnson and S.J. Bis, Tetrahedron Letters, 33(48), 7287-7290 (1992), Theil, et al., Liebigs Ann. Chem., 195-200 (1991), Theil, et al., Tetrahedron, 47(36), 7569-7582 (1991) and Theil, et al., Synthesis, 540 (1988), to provide the compounds of formula (IIb) and (IV).

10

For example, a compound of formula (II) is dissolved in a suitable solvent or solvent mixture, such as tert-butyl methyl ether, diethyl ether, diisopropyl ether, tetrahydrofuran, cyclohexane, toluene, hexane and the like.

- 15 The preferred suitable solvents are tert-butyl methyl ether and cyclohexane. The solution is treated with a suitable enzyme and an excess of a suitable acylating agent.

Examples of suitable acylating agents are isopropenyl acetate, isopropenyl propionate, isopropenyl butyrate, vinyl acetate, vinyl propionate, vinyl butyrate and the like. The preferred suitable acylating agent is vinyl acetate. About 0.70 equivalents of an alkyl amine, such as triethylamine, may be optionally added, with stirring, at a temperature of about 15°C to about 55°C. A suitable enzyme

- 25 is an enzyme that catalyzes the enantioselective acylation of the compound of formula (II) whereby essentially only a single enantiomer of the racemic mixture, such as the compound of formula (IIa), is acylated under the described conditions to produce a mixture of compounds of formula (IV) and of formula (IIb), wherein Z is acetyl, propionyl or butyryl. Examples of suitable enzymes are pancreatin (available from Sigma Chemical Company), Candida antarctica lipase B (Novo Nordisk SP 435), lipozyme IM (available from Novo Nordisk) and the like. The preferred
- 35 suitable enzyme is pancreatin. The preferred temperature is 22°C. The reaction is then stirred for about 6 hours to 24 hours, preferably about 8 hours. The reaction is then filtered through diatomaceous earth and the filtrate is

22

concentrated under vacuum to provide a mixture of compounds of formula (IIb) and (IV). The resulting mixture of compounds of formula (IIb) and (IV) are readily separated from one another by techniques and procedures well known to one of ordinary skill in the art, such as chromatography or distillation. For example, the mixture can be chromatographed on silica gel with a suitable eluent, such as ethyl acetate/hexane to provide a clean separation of compounds of formula (IIb) from compounds of formula (IV).

In Scheme II, step B, the compounds of formula (IV) can be selectively hydrolyzed by procedures well known to one of ordinary skill in the art to produce the compounds of formula (IIa). For example, the compound of formula (IV) wherein Pg is a tetrahydro-pyran-2-yl protecting group, or a trialkylsilyl protecting group, such as a tert-butyldimethylsilyl group, can be dissolved in a suitable solvent or solvent mixture, such as THF/methanol/water, and treated with one equivalent of a suitable base, such as lithium hydroxide monohydrate. The reaction is stirred at room temperature for about 1 to 8 hours and the product is then isolated and purified by techniques well known in the art, such as extractive methods and chromatography. For example, the reaction is diluted with a suitable organic solvent, such as diethyl ether, rinsed with water, dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum. The residue is then purified by chromatography on silica gel with a suitable eluent, such as ethyl acetate/hexane, to provide the compound of formula (IIa).

In Scheme II, step C, the compounds of formula (IV) can be selectively hydrolyzed by procedures well known to one of ordinary skill in the art to produce compounds of formula (V). For example, the compound of formula (IV) wherein Pg is a tetrahydro-pyran-2-yl protecting group can be dissolved in a suitable organic solvent such as ethanol,

23

and treated with p-toluenesulfonic acid. In addition, the compound wherein Pg is a tert-butyldimethylsilyl group on formula (IV), can be dissolved in a suitable organic solvent, such as tetrahydrofuran, and treated with n-tetrabutylammonium fluoride. Either reaction is then stirred at room temperature for about 1 to 8 hours and the product is then isolated and purified by techniques well known in the art, such as extractive methods and chromatography. For example, either reaction is diluted with a suitable organic solvent, such as diethyl ether, rinsed with water, dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum. The residue is then purified by chromatography on silica gel with a suitable eluent, such as ethyl acetate/hexane, to provide the compound of formula (V).

The compounds of formulas (IIb) and (IIa) can then be readily converted to the corresponding enantiomers of O-protected 4-hydroxy-2-cyclopentenone by procedures known to one of ordinary skill in the art. For example, the procedures described by M. Asami, Tetrahedron Letters, 26(47), 5803-5806 (1985), K. Laumen and M Schneider, Tetrahedron Letters, 25(51), 5875-5878 (1984), M. Nara, et al., Tetrahedron, 36, 3161-3170 (1980) and J. Nokami, et al., Tetrahedron Letters, 32(21), 2409-2412 (1991), can be followed in an analogous manner to produce both enantiomers of O-protected-4-hydroxy-2-cyclopentenone. For example, the compound of formulas (IIa) or (IIb) is dissolved in a suitable organic solvent, such as methylene chloride and treated with a suitable oxidizing agent, such as manganese dioxide (MnO₂), pyridinium dichromate (PDC) or pyridinium chlorochromate (PCC) to provide the ketones of formulas (Ia) and (Ib). The compounds of formulas (IIa) and (IIb) are useful synthetic intermediates for the enantioselective synthesis of prostaglandins, for example see M. Asami, Tetrahedron Letters, 26(47), 5803-5806 (1985). In addition, the enantiomers of formulas (Ia) and (Ib) can be

24
prepared in general following the procedure of Corey, E.J.,
et al., Tetrahedron Letters, 27, 2199 (1986) or S.P.
Khanapure et al., J. Org. Chem., 60, 7548-7551 (1995).

5

Compounds of the formulas (VIa), (VIb), (VII) and
(VIII) can be prepared as described in Scheme III. All the
substituents, unless otherwise indicated, are previously
defined. The reagents and starting materials are readily
10 available to one of ordinary skill in the art.

15





20

25

30

35

25
Scheme III



26

In Scheme III the compound of formula (VI) is prepared by one of ordinary skill in the art, for example, by reduction of the double bond in the compound of formula (II). More specifically, the compound of formula (II) is combined with Ni_2B in a suitable organic solvent, such as methanol and the reaction mixture is stirred for about 15-20 hours at room temperature under an atmosphere of hydrogen. The product is then isolated and purified by techniques and procedures well known in the art. For example, the hydrogen atmosphere is purged with nitrogen, the reaction mixture is filtered through diatomaceous earth, the solids washed with methanol and the filtrate concentrated under vacuum. The residue can then be purified by column chromatography or vacuum distillation to provide the purified compound of formula (VI).

In Scheme III, step A, the compound of formula (VI) is subjected to an enzyme catalyzed enantioselective acylation reaction under analogous conditions well known in the art, such as that described by Johnson, C.R., et al., Tetrahedron Letters, 35(12), 1833-1834 (1994), C.R. Johnson and S.J. Bis, Tetrahedron Letters, 33(48), 7287-7290 (1992), Theil, et al., Liebigs Ann. Chem., 195-200 (1991), Theil, et al., Tetrahedron, 47(36), 7569-7582 (1991) and Theil, et al., Synthesis, 540 (1988), to provide the compounds of formula (VIb) and (VII).

For example, a compound of formula (VI) is dissolved in a suitable solvent or solvent mixture, such as tert-butyl methyl ether, diethyl ether, diisopropyl ether, tetrahydrofuran, cyclohexane, toluene, hexane and the like. The preferred suitable solvents are tert-butyl methyl ether and cyclohexane. The solution is treated with a suitable enzyme and an excess of a suitable acylating agent. Examples of suitable acylating agents are isopropenyl acetate, isopropenyl propionate, isopropenyl butyrate, vinyl acetate, vinyl propionate, vinyl butyrate and the

27

like. The preferred suitable acylating agent is vinyl acetate. About 0.70 equivalents of an alkyl amine, such as triethylamine, may be optionally added, with stirring, at a temperature of about 15°C to about 55°C. The preferred temperature is about 22°C. A suitable enzyme is an enzyme that catalyzes the enantioselective acylation of the compound of formula (VI) whereby essentially only a single enantiomer of the racemic mixture, such as the compound of formula (VIa), is acylated under the described conditions to produce a mixture of compounds of formula (VII) and of formula (VIb), wherein Z is acetyl, propionyl or butyryl. Examples of suitable enzymes are pancreatin (available from Sigma Chemical Company), Candida antarctica lipase B (Novo Nordisk SP 435), lipozyme IM (available from Novo Nordisk) and the like. The preferred suitable enzyme is pancreatin. The reaction is then stirred for about 6 hours to about 30 hours, preferably about 8 hours. The reaction is then filtered through diatomaceous earth and the filtrate is concentrated under vacuum to provide a mixture of compounds of formula (VIb) and (VII). The resulting mixture of compounds of formula (VIb) and (VII) are readily separated from one another by techniques and procedures well known to one of ordinary skill in the art, such as chromatography or distillation. For example, the mixture can be chromatographed on silica gel with a suitable eluent, such as ethyl acetate/hexane to provide a clean separation of compounds of formula (VIb) from compounds of formula (VII).

In Scheme III, step B, the compounds of formula (VII) can be selectively hydrolyzed by procedures well known to one of ordinary skill in the art to produce the compounds of formula (VIa). For example, the compound of formula (VII) wherein Pg is a tetrahydro-pyran-2-yl protecting group, or a trialkylsilyl protecting group, such as a tert-butyldimethylsilyl group, can be dissolved in a suitable solvent or solvent mixture, such as THF/methanol/water, and treated with one equivalent of a suitable base, such as

28

lithium hydroxide monohydrate. The reaction is stirred at room temperature for about 1 to 8 hours and the product is then isolated and purified by techniques well known in the art, such as extractive methods and chromatography. For example, the reaction is diluted with a suitable organic solvent, such as diethyl ether, rinsed with water, dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum. The residue is then purified by chromatography on silica gel with a suitable eluent, such as ethyl acetate/hexane, to provide the compound of formula (VIa).

In Scheme III, step C, the compounds of formula (VII) can be selectively hydrolyzed by procedures well known to one of ordinary skill in the art to produce compounds of formula (VIII). For example, the compound of formula (VII) wherein Pg is a tetrahydro-pyran-2-yl protecting group can be dissolved in a suitable organic solvent such as ethanol, and treated with p-toluenesulfonic acid. In addition, the compound wherein Pg is a tert-butyldimethylsilyl group on formula (IV), can be dissolved in a suitable organic solvent, such as tetrahydrofuran, and treated with n-tetrabutylammonium fluoride. Either of the above reaction mixtures is then stirred at room temperature for about 1 to 8 hours and the product is then isolated and purified by techniques well known in the art, such as extractive methods and chromatography. For example, either of the above reaction mixtures is diluted with a suitable organic solvent, such as diethyl ether, rinsed with water, dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum. The residue is then purified by chromatography on silica gel with a suitable eluent, such as ethyl acetate/hexane, to provide the compound of formula (VIII).

The compounds of formulas (VIb) and (VIa) can then be readily converted to the corresponding enantiomers of O-

29

protected 3-hydroxycyclopentanone by procedures known to one of ordinary skill in the art. For example, the compound of formulas (VIa) or (VIb) is dissolved in a suitable organic solvent, such as methylene chloride and treated with a suitable oxidizing agent, such as pyridinium dichromate (PDC), pyridinium chlorochromate (PCC) or Swern conditions to provide the corresponding ketones.

10 The following examples present typical syntheses as described in Schemes I, II and III. These examples are understood to be illustrative only and are not intended to limit the scope of the present invention in any way.

15 Gas chromatography retention times reported herein are obtained under the following conditions; a Hewlett Packard 5890 Series II Gas Chromatograph is utilized, with a 30 m x 0.32 mm HP-5 cross-linked, 5% PH ME silicone column fitted thereto. The flow rate is set at 30 mL/min
20 with helium as the carrier gas. The injection port temperature is 200°C, the detector temperature is 275°C and the program used is a gradient wherein the initial temperature is set at 100°C for 10 minutes and then it is increased at a rate of 10°C/minute to 200°C where it is held
25 for 5 minutes prior to terminating.

In addition, chiral chromatography is readily utilized by one of ordinary skill in the art to determine the ee of a particular compound. For example, a CDX- β 10 m X 0.25 mm
30 id (available from J & W Scientific, Folsom, CA) can be utilized under standard conditions, such as a column temperature of 100°C, injector temperature of 200°C and detector temperature of 220°C. Alternatively, the ee of a particular compound can be determined by preparing the
35 corresponding Mosher's Esters of the compounds from (R)-(+)- α -methoxy- α -(trifluoromethyl)phenylacetic acid or (S)-(-)- α -methoxy- α -(trifluoromethyl)phenylacetic acid utilizing techniques well known to one of ordinary skill in

the art, for example see Dale,³⁰ J.A., Dull, D.L. and Mosher, H.S, J. Org. Chem., 34(9), 2543-2549 (1969). The amounts of each resulting diastereomer can be determined by ¹⁹F NMR
5 or separation by column chromatography, chiral column chromatography or gas chromatography, as is well known in the art, thereby allowing calculation of the ee of the compound.

10 As used herein, the following terms have the indicated meanings: "g" refers to grams; "mmol" refers to millimoles; "ml" refers to milliliters; "bp" refers to boiling point; "mp" refers to melting point; "°C" refers to degrees Celsius; "mmHg" refers to millimeters of mercury; "μL"
15 refers to microliters; "μg" refers to micrograms; and "μM" refers to micromolar; "R_f" refers to retention factor; "δ" refers to parts per million downfield from tetramethylsilane; "[α]_D²⁰" refers to specific rotation of the D line of sodium at 20°C obtained in a 1 decimeter
20 cell; "c" refers to concentration in g/mL; "DMF" means dimethylformamide; "THF" means tetrahydrofuran; "TBME" means tert-butyl methyl ether; "NMM" means N-methylmorpholine; "DMSO" means dimethylsulfoxide; and "DMAP" means 4-dimethylaminopyridine.

25


30

35

37
Example 1

Preparation of 4-hydroxy-2-cyclopentenone .

5



10

Scheme I, step a; A solution of furfuryl alcohol (125 g, 1.27 mol) in water (3.7 L) is treated with KH_2PO_4 (6.3 g, 46.3 mmol). The pH of the solution is adjusted to pH 4.1 (pH meter) with H_3PO_4 and then heated to 99°C under an atmosphere of nitrogen for 40 hours. The solution is then cooled and washed with methylene chloride (2×500 mL). The organic layers are combined and extracted with water (2×500 mL). The aqueous layer and aqueous extracts are combined and concentrated under vacuum (70°C , 20 mm Hg) to provide an oil. The oil is dissolved in methylene chloride (1 L), dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum to provide the title compound (66 g, 53%) as a dark oil; ^1H NMR (CDCl_3) δ 7.61 (dd, $J = 5.6$, 4.8 Hz, 1H), 6.20 (dd, $J = 5.6$, 4.8 Hz, 1H), 5.01-5.04 (m, 1H), 3.61 (bs, 1H), 2.75 (dd, $J = 18.5$, 3.2 Hz, 1H), 2.26 (dd, $J = 18.5$, 6.0 Hz, 1H); ^{13}C NMR (CDCl_3) δ 207.4, 164.0, 134.7, 70.1, 44.1; IR (neat) ν_{max} 3387, 2974, 1711 cm^{-1} ; MS (EI) m/e (% relative intensity) 98 (M^+ , 100).


Anal. Calcd for $\text{C}_5\text{H}_6\text{O}_2 \cdot 0.16\text{H}_2\text{O}$: C, 59.47; H, 6.30, H_2O , 2.9. Found: C, 59.56; H, 6.52, H_2O , 3.0.

35

32
Example 2

Preparation of 4-tert-butyldimethylsiloxy-2-cyclopentenone.

5



10 Scheme I, step b; A solution of 4-hydroxy-2-cyclopentenone (191 g, 1.95 mol, prepared in example 1) and triethylamine (430 mL, 3.09 mol) in anhydrous tetrahydrofuran (1 L) is treated with 4-

15 dimethylaminopyridine (4.90 g, 40.0 mmol). The solution is cooled to 0°C and treated portionwise, over 10 minutes, with tert-butyldimethylsilyl chloride (278 g, 1.84 mol) maintaining the temperature at or below 10°C. The reaction is then allowed to stir overnight at room temperature. It is then poured into aqueous HCl (0.5 N, 1 L). The phases

20 are separated and the aqueous phase is extracted with heptane (2 × 1 L). The organic phase and organic extracts are combined, washed with aqueous HCl (0.5 N, 2 × 500 mL), then 5% sodium bicarbonate (500 mL), then brine (500 mL), dried over anhydrous magnesium sulfate, filtered and

25 concentrated under vacuum (40°C, 20 mmHg) to provide the title compound (325 g). This is purified by Kugelrohr distillation (70-80°C, 1 mmHg) to provide the title compound (282 g, 72% yield) as a light yellow oil, R_f =0.55, 20% ethyl acetate/hexane, GC retention time is 14.97 minutes; ^1H NMR (CDCl_3) δ 7.48 (dd, J = 5.7, 2.4 Hz, 1H), 6.20 (d, J = 5.7 Hz, 1H), 4.95-4.99 (m, 1H), 2.72 (dd, J = 18.2, 6.0 Hz, 1H), 2.25 (dd, J = 18.2, 2.3 Hz, 1H), 0.88 (s, 9H), 0.11 (s, 6H); ^{13}C NMR (CDCl_3) δ 206.4, 163.8, 134.4, 70.8, 44.9, 25.7, 25.6, 18.0; IR (neat) ν_{max} 2957, 2931, 2887, 2858, 1725 cm^{-1} ; MS (EI) m/e (% relative intensity) 212 (M^+ , 5), 155 (M^+-57 , 100).

35


Anal. Calcd for $\text{C}_{11}\text{H}_{20}\text{O}_2\text{Si}$: C, 62.21; H, 9.51.

33

Found: C, 62.39; H, 9.50.

Example 3a5 Preparation of cis-4-tert-butyldimethylsilyloxy-2-
cyclopentenol.

10



Scheme I, step c; A mechanically stirred solution of 4-tert-butyldimethylsiloxy-2-cyclopentenone (50.2 g, 236 mmol) in anhydrous toluene (1 L) under an atmosphere of argon is treated with lithium iodide (160 g, 1.20 mol). The mixture is cooled to -20°C and treated with lithium aluminum hydride (9.0 g, 237 mmol) in one portion. The reaction is then stirred for 5 minutes and anhydrous tert-butyl methyl ether (200 mL) is added at a rate that maintains the temperature of the reaction at or below -15°C (total addition time is approximately 3 minutes). The reaction is stirred for one hour at -20°C and then it is quenched by slow addition of aqueous sodium hydroxide (1N, 250 mL) at a rate that maintains the temperature of the reaction below 20°C . The resulting suspension is then filtered through a pad of diatomaceous earth and the pad is subsequently rinsed with toluene (400 mL). The filtrate phases are separated and the aqueous phase is extracted with toluene (300 mL). The organic phase and organic extract are combined, rinsed with aqueous sodium hydroxide (1N, 300 mL), brine (300 mL), dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum (40°C , 20 mmHg). The residue is then purified by Kugelrohr distillation ($60-80^{\circ}\text{C}$, 1 mmHg) to provide the title compound (37.4 g, 74% yield) as a colorless oil; cis/trans/1-2 + 1-4 addition, 95.3/2.1/2.6; $R_f=0.20$, 20% ethyl acetate/hexane, GC retention time for the title compound is 13.95 minutes, while GC retention times for the byproducts corresponding

34

to compounds 3 (trans) and 4 (1-2 + 1-4 addition) in Scheme I wherein Pg is a TBDMS group are 14.45 min. and 14.06 min. respectively; for the title compound, ^1H NMR (CDCl_3) δ 5.93 (dt, $J = 5.5, 1.7$ Hz, 1H), 5.84 (dt, $J = 5.5, 1.6$ Hz, 1H), 4.63-4.68 (m, 1H), 4.52-4.62 (m, 1H), 2.76-2.86 (bs, 1H), 2.69 (dt, $J = 13.8, 7.1$ Hz, 1H), 1.52 (dt, $J = 13.8, 4.7$ Hz, 1H), 0.90 (s, 9H), 0.09 (s, 6H); ^{13}C NMR (CDCl_3) δ 136.7, 135.6, 75.1, 75.0, 44.5, 25.9, 18.1; IR (neat) ν_{max} 3373, 2957, 2932 cm^{-1} ; MS (EI) m/e (% relative intensity) 157 ($\text{M}^+ - 57$).

Example 3b

Preparation of cis-4-tert-butyldimethylsilyloxy-2-cyclopentenol.

Scheme I, step c; A mechanically stirred solution of 4-tert-butyldimethylsilyloxy-2-cyclopentenone (175 g, 824 mmol) in anhydrous toluene (1.5 L) under an atmosphere of argon is treated with lithium iodide (240 g, 1.79 mol). The mixture is cooled to -20°C and treated with lithium aluminum hydride (13.5 g, 356 mmol) in one portion. The reaction is then stirred for 5 minutes and anhydrous tert-butyl methyl ether (300 mL) is added at a rate that maintains the temperature of the reaction at or below -15°C (total addition time is approximately 3 minutes). The reaction is stirred for 3 hours at -20°C and then it is quenched by slow addition of aqueous sodium hydroxide (1N, 250 mL) at a rate that maintains the temperature of the reaction below 20°C . The resulting suspension is then filtered through a pad of diatomaceous earth and the pad is subsequently rinsed with toluene (400 mL). The filtrate phases are separated and the aqueous phase is extracted with toluene (450 mL). The organic phase and organic extract are combined, rinsed with aqueous sodium hydroxide (1N, 450 mL), brine (450 mL), dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum (40°C , 20 mmHg). The residue is then purified by Kugelrohr distillation ($60-80^\circ\text{C}$, 1 mmHg) to provide the title compound

35

(120 g, 68% yield) as a colorless oil; cis/trans/1-2 + 1-4 addition, 92/4/4.

5

Example 3cPreparation of cis-4-tert-butyldimethylsilyloxy-2-cyclopentenol.

Scheme I, step c; A mechanically stirred solution of 4-tert-butyldimethylsilyloxy-2-cyclopentenone (1.01 g, 4.76 mmol) in anhydrous ethyl ether (20 mL) under an atmosphere of argon is treated with lithium iodide (3.20 g, 23.9 mmol). The mixture is cooled to -78°C and treated with lithium aluminum hydride (184 mg, 4.85 mmol) in one portion. The reaction is then stirred for 90 minutes. It is then quenched by slow addition of aqueous sodium hydroxide (1N, 23 mL) at a rate that maintains the temperature of the reaction below 20°C. The resulting suspension is then filtered through a pad of diatomaceous earth and the pad is subsequently rinsed with ether. The filtrate phases are separated and the aqueous phase is extracted with ether (20 mL). The organic phase and organic extract are combined, rinsed with aqueous sodium hydroxide (1N, 20 mL), brine (20 mL), dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum (40°C, 20 mmHg). The residue is then purified by Kugelrohr distillation (60-80°C, 1 mmHg) to provide the title compound (820 mg, 80% yield) as a colorless oil; cis/trans/1-2 + 1-4 addition, 88.5/3.3/8.2.

30

Example 3dPreparation of cis-4-tert-butyldimethylsilyloxy-2-cyclopentenol.

Scheme I, step c; A mechanically stirred solution of 4-tert-butyldimethylsilyloxy-2-cyclopentenone (501 mg, 2.36 mmol) in anhydrous toluene (10 mL) under an atmosphere of argon is treated with lithium bromide (1.06 g, 12.2 mmol). The mixture is cooled to -20°C with an ice/salt bath and treated with lithium aluminum hydride (92.0 mg, 2.42 mmol)

36

in one portion followed by tert-butyl methyl ether (1.0 mL). The ice/salt bath is replaced with an ice bath and the reaction is then stirred for 2 hours at 0°C. It is then
5 quenched by slow addition of aqueous sodium hydroxide (1N, 7.0 mL) at a rate that maintains the temperature of the reaction below 20°C. The resulting suspension is then filtered through a pad of diatomaceous earth and the pad is subsequently rinsed with toluene. The filtrate phases are
10 separated and the aqueous phase is extracted with toluene. The organic phase and organic extract are combined, rinsed with aqueous sodium hydroxide (1N), brine, dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum (40°C, 20 mmHg). The residue is then purified
15 by Kugelrohr distillation (60-80°C, 1 mmHg) to provide the title compound (350 mg, 69% yield) as a colorless oil; cis/trans/1-2 + 1-4 addition, 92.7/6.3/1.0.

Example 3e

20 Preparation of cis-4-tert-butyltrimethylsilyloxy-2-cyclopentenol.

Scheme I, step c; A stirred solution of ZnCl₂ (19 mL, 19 mmol, 1M in ether) is treated with 4-tert-butyltrimethylsilyloxy-2-cyclopentenone (2.0 g, 9.42 mmol)
25 under an atmosphere of argon. The solution is cooled to -20°C and treated dropwise with lithium aluminum hydride (9.0 mL, 9.0 mmol, 1M in ether) at such a rate as to keep the reaction temperature at or below -15°C. After stirring for about 2 hours at -20°C, approximately 5 mL of 1N NaOH was
30 added. The reaction is filtered through diatomaceous earth, dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum to provide the title compound (1.3 g); cis/trans/1-2 + 1-4 addition, 81/3/16.

37
Example 3f

Preparation of cis-4-tert-butyldimethylsilyloxy-2-cyclopentenol.

5 Scheme I, step c; A stirred solution of 4-tert-butyldimethylsilyloxy-2-cyclopentenone (2.0 g, 9.42 mmol) in anhydrous toluene (15 mL) under an atmosphere of argon is treated with MgBr₂ (3.5 g, 19.0 mol). The mixture is cooled to -25°C and treated with lithium aluminum hydride (178 mg,
10 4.69 mmol) in one portion, followed by addition of anhydrous tert-butyl methyl ether (3.0 mL). The reaction is stirred at -20°C for 2 hours and then overnight at room temperature. Additional lithium aluminum hydride (178 mg, 4.69 mmol) is added at room temperature and the reaction is
15 stirred for 2 hours. The reaction is then quenched by slow addition of 1N NaOH (5 mL) followed by filtration through diatomaceous earth. The filtrate is dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum to provide the title compound (1.3 g); cis/trans/1-2 + 1-4
20 addition, 90/3/7.

Example 3g

Preparation of cis-4-tert-butyldimethylsilyloxy-2-cyclopentenol with 2.8 mol% tert-butyldimethylsilanol added
25 to the reaction mixture.

 Scheme I, step c; Into a 100 mL flask equipped with a mechanical stirrer, a low temperature thermometer and a 60 mL addition funnel topped with a nitrogen bubbler is placed lithium aluminum hydride (0.5 g, 0.013 mol), lithium iodide
30 (6.7 g, 0.05 mol) and toluene (34 g). The slurry is cooled to -40°C and the addition funnel is charged with 4-tert-butyldimethylsilyloxy-3-cyclopentanone (5.0 g, 0.024 mol, containing 2.8% tert-butyldimethylsilanol as determined by gas chromatography on a Hewlett-Packard 5890 Series II gas
35 chromatograph, a Hewlett-Packard integrator, a Hewlett-Packard column, PH-1, 10m, 0.53mm ID, 2.56µm, injection port at 190°C, detector at 270°C, using a gradient with a starting temperature of 50°C for 2 minutes then increasing

38

at a rate of 20°C/minute to 250°C for 5 minutes) and tert-butylmethyl ether (18 g, TBME). The cyclopentenone/TBME solution is added to the slurry over 5 minutes at such a rate as to maintain the internal reaction temperature between -30°C and -36°C. The reaction mixture is then allowed to warm to -30°C and stir for 4 hours. The reaction is quenched by slow addition of a 5 wt% solution of aqueous ammonium chloride (20 g). Toluene (20 g) is added and the phases are separated. The aqueous phase is then extracted with toluene (30 g). The organic phases are combined, washed with water (30 g), dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum. The residue is purified by vacuum distillation through a 14 cm, packed glass bead (4 mm) column at 0.2 mmHg (63-66°C) to provide the title compound (3.9 g, 77%); cis/trans/1-2 + 1-4 addition, 95/4/1.

Example 3h

20 Preparation of cis-4-tert-butyldimethylsiloxy-2-cyclopentenol with 16 mol% tert-butyldimethylsilanol added to the reaction mixture.

Scheme I, step c; Into a 100 mL flask equipped with a mechanical stirrer, a low temperature thermometer and a 60 mL addition funnel topped with a nitrogen bubbler is placed lithium aluminum hydride (0.5 g, 0.013 mol), lithium iodide (6.7 g, 0.05 mol) and toluene (34 g). The slurry is cooled to -30°C and the addition funnel is charged with 4-tert-butyldimethylsiloxy-3-cyclopentanone (4.3 g, 0.02 mol, containing 2.8% tert-butyldimethylsilanol as determined in example 3g), tert-butyldimethylsilanol (0.6 g, 0.005 mol) and tert-butylmethyl ether (18 g, TBME). The additional tert-butyldimethylsilanol is added to adjust the solution to contain 16% tert-butyldimethylsilanol. The cyclopentenone/silanol/TBME solution is added in one portion resulting in an 8°C exotherm. The reaction mixture is cooled and maintained at between -28°C and -32°C for 1.5 hours. The reaction is then quenched by slow addition of a

39

5 wt% solution of aqueous ammonium chloride (20 g) and the phases are separated. The aqueous phase is extracted with methylene chloride (2 X 20 g). The organic phases are combined, washed with water (20 g), dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum. The residue is purified by vacuum distillation through a 14 cm packed glass bead (4 mm) column at 0.5 mmHg (67-70°C) to provide the title compound (3.5 g, 81%); cis/trans/1-2 + 1-4 addition, 96.3/2.8/0.9.

Example 3I

Preparation of cis-4-tert-butyldimethylsilyloxy-2-cyclopentenol with 17 mol% tert-butyldimethylsilanol added to the reaction mixture.

Scheme I, step c; Into a 100 mL flask equipped with a mechanical stirrer, a low temperature thermometer and a 60 mL addition funnel topped with a nitrogen bubbler is placed lithium aluminum hydride (0.5 g, 0.013 mol), lithium iodide (1.4 g, 0.010 mol) and toluene (34 g). The slurry is cooled to -33°C and the addition funnel is charged with 4-tert-butyldimethylsiloxy-3-cyclopentanone (4.3 g, 0.02 mol, containing 2.8% tert-butyldimethylsilanol as determined in example 3g), tert-butyldimethylsilanol (0.6 g, 0.005 mol) and tert-butylmethyl ether (18 g, TBME). The additional tert-butyldimethylsilanol is added to adjust the solution to contain 17% tert-butyldimethylsilanol. The cyclopentenone/silanol/TBME solution is added in one portion resulting in an internal temperature of -23°C. The reaction mixture temperature is maintained near -30°C for 23 hours and it is then quenched with 5 wt% aqueous ammonium chloride (21 g). The phases are separated and the aqueous phase is extracted with toluene (2 X 20 g). The organic phases are combined, washed with water (25 g), dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum. The residue is purified by vacuum distillation through a 14 cm packed glass bead (4 mm)

column at 0.4 mmHg (65-68°C) ⁴⁰ to provide the title compound (3.2 g, 74%); cis/trans/1-2 + 1-4 addition, 96.2/2.8/1.

5

Example 3J

Preparation of cis-4-tert-butyldimethylsilyloxy-2-cyclopentenol with 18 mol% tert-butyldimethylsilanol added to the reaction mixture.

Scheme I, step c; Into a 100 mL flask equipped with a
10 mechanical stirrer, a low temperature thermometer and a 60 mL addition funnel topped with a nitrogen bubbler is placed lithium aluminum hydride (0.5 g, 0.013 mol) and toluene (30 g). The slurry is cooled to -30°C and the addition funnel is charged with tert-butyldimethylsilanol (0.6 g, 0.005 mol)
15 and toluene (9 g). The silanol/toluene solution is added in one portion resulting in mild gas evolution. The additional tert-butyldimethylsilanol is added to adjust the solution to contain 18% tert-butyldimethylsilanol. The mixture is stirred at a temperature of between -25°C and -
20 30°C for 15 minutes. The addition funnel is charged with 4-tert-butyldimethylsiloxy-3-cyclopentanone (4.3 g, 0.02 mol, containing 2.8% tert-butyldimethylsilanol as determined in example 3g) and tert-butyl methyl ether (13 g, TBME). The cyclopentenone/TBME solution is added in one portion to the
25 slurry resulting in a 9°C exotherm (-21°C internal reaction temperature). The reaction mixture temperature is maintained near -25°C for 1.5 hours and then the reaction is quenched with 5 wt% aqueous ammonium chloride. Toluene (20 g) is added and the phases are separated. The aqueous
30 phase is extracted with toluene (30 g). The organic phases are combined, washed with water (30 g), dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum. The residue is purified by vacuum distillation through a 14 cm packed glass bead (4 mm)
35 column at 0.5 mmHg (67-69°C) to provide the title compound (3.1 g, 72%); cis/trans/1-2 + 1-4 addition, 95/3.9/1.1.

41

Example 3K

Preparation of cis-4-tert-butyldimethylsilyloxy-2-
cyclopentenol with 20 mol% isopropanol added to the
5 reaction mixture.


Scheme I, step c; A slurry of lithium aluminum hydride (350 mg, 9 mmol) and lithium iodide (1.16 g, 8.7 mmol) in toluene (34 mL) is cooled to -30°C and treated with a solution of 4-tert-butyldimethylsiloxy-3-cyclopentanone
10 (3.509 g, 16.5 mmol), tert-butyl methyl ether (17 mL) and isopropanol (0.25 mL, 20 mol%) dropwise over 22 minutes. The temperature rises to -25°C. The reaction is then stirred for 2.5 hours at -20°C to -25°C. Then saturated ammonium chloride (20 mL) is added to the reaction followed
15 by water (5 mL). The reaction is warmed to room temperature and then filtered. The solids are rinsed with toluene (20 mL). The phases of the filtrate are separated. The aqueous phase is extracted with toluene (20 mL). The organic phases are combined, dried over anhydrous magnesium
20 sulfate, filtered and concentrated under vacuum. The residue is purified by Kugelrohr distillation (0.4 mmHg/ 60-75°C) to provide a colorless oil (2.17 g, 61%); cis/trans/1-2 + 1-4 addition, 95.9/3.1/1.

25

Example 4

Preparation of cis-2-cyclopentenyl-1,4-diol.

30



Scheme I, step d; A solution of cis-4-tert-butyldimethylsilyloxy-2-cyclopentenol (50 g, 0.233 mol) in tetrahydrofuran (250 mL) at room temperature is treated
35 sequentially with triethylamine (5.00 mL, 0.036 mol) and tetrabutylammonium fluoride (250 mL of a 1.0 N solution in tetrahydrofuran, 0.250 mol). The reaction is stirred for 3 hours and then concentrated under vacuum (40°C, 20 mmHg).

42

The residue is then purified by chromatography (silica gel, 100 x 160 mm, 10% acetone/ethyl acetate) followed by recrystallization from chloroform to provide the title compound (18.0 g, 77%) as white needles; mp 57-58°C, R_f = 0.25 (10% acetone/ethyl acetate); ^1H NMR (CDCl_3) δ 6.01 (s, 2H), 4.62-4.68 (m, 1H), 4.02 (d, J = 7.3 Hz, 1H), 2.73 (dt, J = 14.6, 7.3 Hz, 1H), 1.57 (dt, J = 14.5, 3.4 Hz, 1H); ^{13}C NMR (CDCl_3) δ 136.3, 74.9, 43.3; IR (KBr) ν_{max} 3402, 3391, 3364 cm^{-1} ; MS (CI) m/e (% relative intensity) 83 ($\text{M}^+ + \text{H} - \text{H}_2\text{O}$, 100).

Anal. Calcd for $\text{C}_5\text{H}_8\text{O}_2$: C, 59.98; H, 8.05.


Found: C, 59.79; H, 8.36.

15

Example 5

Preparation of 4-(tetrahydro-pyran-2-yloxy)-cyclopent-2-enone.

20



25

Scheme I, step b; A solution of 4-hydroxy-2-cyclopentenone (1.41 g, 14.4 mmol) in tetrahydrofuran (24 mL) is treated with 3,4-dihydro-2H-pyran (2 mL) and pyridinium p-toluenesulfonate (500 mg, PPTS). The reaction is stirred at room temperature for 18 hours. The reaction mixture is then diluted with ethyl acetate (25 mL) and washed with 50% saturated brine (2 x 30 mL). The organic layer is dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum. The resulting crude brown oil is purified by filtration through a plug of silica gel (25 g, 33% ethyl acetate/hexane) to provide the title compound as a yellow oil (2.00g, 76%); ^1H NMR (CDCl_3) δ

43


7.46 (2 x dd, 1H, J=16.3, 5.7 Hz), 6.2 (m, 1H), 4.9 (m, 1H), 4.80 (d appt, 1H, J=23.8, 2.9 Hz), 3.9 (m, 1H), 3.6 (m, 1H), 2.73 (2 x dd, 1H, J=18.4, 6.2 Hz), 2.35 (2 x d, 1H, J=18.4 Hz), 1.8 (m, 1H), 1.6 (m, 4H); IR (neat) $\nu_{\max}$ 2944, 2870, 2855, 1723, 1348, 1202, 1182, 1152, 1128, 1078, 1032 cm^{-1} ; MS (CI) m/e (% relative intensity) 183 ($\text{M}+\text{H}^+$, 28), 85(100).

10

Example 6

Preparation of cis-4-(tetrahydro-pyran-2-yloxy)-cyclopent-2-enol.

15



20 Scheme I, step c; A slurry of lithium aluminum hydride (222 mg, 5.8 mmol), lithium iodide (3.2 g, 24 mmol), tert-butyl methyl ether (6 mL) and toluene (16 mL) is cooled to -15°C . A solution of 4-(tetrahydro-pyran-2-yloxy)-cyclopent-2-enone (2.179 g, 11.97 mmol, prepared in example 25) in tert-butyl methyl ether (2 mL) and toluene (2 mL) is added dropwise over 40 minutes. The reaction mixture is allowed to stir for 30 minutes. Then sodium hydroxide (1N, 5 mL) is added slowly to the reaction mixture. The slurry is filtered and the resulting phases separated. The 30 aqueous phase is extracted with ethyl acetate (2 x 10 mL). The organic extracts are combined with the organic phase, dried over magnesium sulfate, filtered and concentrated under vacuum. The crude oil is then purified by chromatography (silica gel, 30 g, 50% ethyl acetate/hexane, 35 400 mL) to provide the title compound (1.62 g, 73%), cis/trans/1-2 + 1-4 addition, 88/8/4; ^1H NMR (CDCl_3) δ 6.1 (m, 1H), 4.7 (m, 1H), 4.6 (m, 2H), 3.9 (m, 1H), 3.5 (m, 1H), 2.7 (m, 1H), 1.4-2.0 (m, 8H); ^{13}C NMR (CDCl_3) δ

137.2, 137.1, 134.8, 133.6, 98.3, 97.8, 79.7, 79.5, 74.7, 74.5, 62.6, 62.5, 42.0, 41.1, 31.1, 30.9, 25.4, 19.6, 19.5; IR (neat) $\nu_{\max}$ 2944, 2870, 2855, 1723, 1348, 1202, 1182, 1152, 1128, 1078, 1032 cm^{-1} ; MS (CI) m/e (% relative intensity) 183 ($\text{M}+\text{H}^+$, 7), 167 ($\text{M}+\text{H}^+-\text{H}_2\text{O}$, 40), 85(100).

Example 7

Preparation of cis-2-cyclopentenyl-1,4-diol.

10 Scheme I, step d; A solution of cis-4-(tetrahydropyran-2-yloxy)-cyclopent-2-enol (338 mg, prepared in example 6) in ethanol (4 mL) is treated with p-toluenesulfonic acid monohydrate (38 mg, p-TsOH $\cdot$ H₂O). The reaction is stirred at room temperature for 2 hours.


15 Potassium carbonate (116 mg) is added and the reaction mixture is diluted with 25% hexane/ethyl acetate (10 mL). This solution is poured onto a plug of silica gel (10 g) and eluted with 25% hexane/ethyl acetate (3 $\times$ 30 mL) and ethyl acetate (2 $\times$ 40 mL) to provide the title compound

20 (167 mg, 90%), cis/trans/1-2 + 1-4 addition, 88/8/4.

Example 8

Preparation of 4-tert-butoxy-cyclopent-2-enone.

25



30

30 Scheme I, step b; A solution of 4-hydroxy-2-cyclopentenone (1.15 g, 11.7 mmol) in methylene chloride is cooled to 3°C and treated sequentially with tert-butyl trichloroacetimidate (4.2 mL, 23.7 mmol) and boron trifluoride diethyl etherate (0.15 mL). The reaction

35 mixture is stirred at 3-10°C for 2 hours and then allowed to warm to room temperature and stirred for 22 hours. The reaction mixture is then treated with sodium bicarbonate (250 mg) and filtered. The filtrate is concentrated under

45


vacuum and the residue is purified by chromatography (silica gel, 39 g, 20% ethyl acetate/hexane, 600 mL) to provide the title compound (355 mg, 40%) as a yellow oil; ¹H NMR (CDCl₃) δ 7.44 (dd, 1H, J=18 Hz), 6.2 (d, 1H, J=5.4 Hz), 4.8 (m, 1H), 2.68 (dd, 1H, J=5.8, 18 Hz), 2.25 (d, 1H, J=18 Hz), 1.27 (s, 9H); IR (neat) ν_{max} 2976, 2936, 1721, 1368, 1352, 1188, 1103, 1161 cm⁻¹; MS (CI) m/e (% relative intensity) 155 (M+H⁺, 22), 99 (100).

10

Example 9

Preparation of cis-4-tert-butyloxy-cyclopent-2-enol.

15




Scheme I, step C; A slurry of lithium aluminum hydride (55 mg, 1.44 mmol), lithium iodide (1.65 g, 5.76 mmol), tert-butyl methyl ether (2 mL) and toluene (3 mL) is cooled to -15°C. The slurry is treated dropwise with 4-tert-butoxy-cyclopent-2-enone (430 mg, 2.79 mmol, dissolved in 1 mL of toluene) over 5 minutes. The reaction mixture is stirred at -20°C to -12°C for 2 hours and then allowed to warm to room temperature and is stirred for 30 minutes. The reaction mixture is then treated sequentially with sodium hydroxide (1N, 1 mL), then tert-butyl methyl ether (10 mL) and filtered. The phases of the filtrate are separated and the aqueous phase is extracted with tert-butyl methyl ether (15 mL). The organic extracts and organic phase is combined, dried over magnesium sulfate, filtered and concentrated under vacuum. The residue is purified by chromatography (silica gel, 30 g, 33% ethyl acetate/hexane) to provide the title compound (183 mg, 42%) as a yellow oil, cis/trans/1-2 + 1-4 addition, 87/9.8/3.2; ¹H NMR (CDCl₃) δ 5.9 (m, 1H), 5.8 (m, 1H), 4.6 (m, 1H), 4.5 (m, 1H), 2.7 (m, 1H), 2.0 (d, 1H, J=9.6 Hz), 1.5 (d appt,

⁴⁶
¹H, J=4.5, 14 Hz), 1.2 (s, 9H); ¹³C NMR (CDCl₃) δ 136.6, 136, 75.5, 74.4, 74, 44.6, 28.7; ν_{max} 3395, 2974, 2938, 2907, 2878, 1389, 1364, 1117, 1169, 1022 cm⁻¹; MS (CI) m/e (% relative intensity) 157 (M+H⁺-H₂O), 57, 83 (100).

Example 10


Preparation of (-)-cis-4-tert-butyldimethylsilyloxy-2-cyclopentenol (A) and (-)-acetic acid 4-tert-butyldimethylsilyloxy-cyclopent-2-enyl ester (B).



Scheme II, step A; Cis-4-tert-butyldimethylsilyloxy-2-cyclopentenol (10.0 g, 46.6 mmol, prepared in example 3a) is dissolved in tert-butyl methyl ether (60 mL, anhydrous). To the solution is added triethylamine (4.5 mL, 32.3 mmol), pancreatin (30 g, available from Sigma Chemical Company), and vinyl acetate (22 mL, 239 mmol). The reaction is allowed to stir for 7 hours at room temperature. The reaction is then filtered through diatomaceous earth and the filtrate is concentrated under vacuum. The products are separated by chromatography on silica gel (5% to 20% ethyl acetate/hexane) to provide (-)-acetic acid 4-tert-butyldimethylsilyloxy-cyclopent-2-enyl ester (B, 6.1 g, 51% yield, 99% ee), [α]_D -0.2°, (c = 0.52, chloroform) as a yellow oil and (-)-cis-4-tert-butyldimethylsilyloxy-2-cyclopentenol (A, 4.7 g, 47% yield, >99% ee), [α]_D -18.6°, (c = 1.01, chloroform) as a yellow oil.

⁴⁷
Example 11

Preparation of (-)-cis-4-(tetrahydro-pyran-2-yloxy)-cyclopent-2-enol (A) and (-)-acetic acid cis-4-(tetrahydro-pyran-2-yloxy)-cyclopent-2-enyl ester (B).



Scheme II, step A; Cis-4-(tetrahydro-pyran-2-yloxy)-cyclopent-2-enol (1.091 g, 5.92 mmol, prepared in example 6) is dissolved in tert-butyl methyl ether (8.6 mL, anhydrous). To the solution is added triethylamine (0.59 mL, 4.2 mmol), pancreatin (3.2 g, available from Sigma Chemical Company), and vinyl acetate (2.7 mL, 29 mmol). The reaction is allowed to stir for 7 hours at room temperature. The reaction is then filtered through diatomaceous earth and the filtrate is concentrated under vacuum. The products are separated by chromatography on silica gel (10% to 20% ethyl acetate/hexane) to provide (-)-acetic acid cis-4-(tetrahydro-pyran-2-yloxy)-cyclopent-2-enyl ester (B, 601 mg, 45% yield, 91% ee), $[\alpha]_D = -19.8^\circ$, (c = 1.00, chloroform) as a yellow oil and (-)-cis-4-(tetrahydro-pyran-2-yloxy)-cyclopent-2-enol (A, 560 mg, 50% yield, 94% ee), $[\alpha]_D = -9.9^\circ$, (c = 1.06, chloroform) as a yellow oil.


30 (-)-cis-4-(tetrahydro-pyran-2-yloxy)-cyclopent-2-enol
Anal. Calcd for $C_{11}H_{16}O_3 \cdot 0.13H_2O$: C, 64.38; H, 8.78.
Found: C, 64.32; H, 8.97.

35 (-)-acetic acid cis-4-(tetrahydro-pyran-2-yloxy)-cyclopent-2-enyl ester
Anal. Calcd for $C_{12}H_{18}O_4$: C, 63.70; H, 8.01.
Found: C, 63.42; H, 8.09.

48
Example 12

Preparation of (+)-cis-4-tert-butyldimethylsilyloxy-2-cyclopentenol.

5



10 Scheme II, step B; Dissolve (-)-acetic acid 4-tert-butyldimethylsilyloxy-cyclopent-2-enyl ester (2.3 mmol, prepared in example 10) in THF/methanol/water (2.7/0.9/0.9 mL). Add lithium hydroxide monohydrate (2.5 mmol) with stirring. After stirring for about 3 hours at room


15 temperature, dilute the reaction with water (10 mL) and extract with tert-butyl methyl ether. Combine the organic phases, dry over anhydrous magnesium sulfate, filter and concentrate under vacuum. Purify the residue by flash chromatography (silica gel, 20% ethyl acetate/hexane) to

20 provide the title compound (452 mg, 92% yield), $[\alpha]_D^{20} = +21.8^\circ$, (c = 1.02, chloroform).

Example 13

Preparation of (+)-cis-4-(tetrahydro-pyran-2-yloxy)-cyclopent-2-enol.

25



30 Scheme II, step B; Dissolve (-)-acetic acid cis-4-(tetrahydro-pyran-2-yloxy)-cyclopent-2-enyl ester (106 mg, 0.47 mmol, prepared in example 11) in THF/methanol/water (1.5/0.5/0.5 mL). Add lithium hydroxide monohydrate (0.57 mmol) with stirring. After stirring for about 3 hours at


35 room temperature, dilute the reaction with tert-butyl methyl ether (10 mL) and water (10 mL). Extract with tert-butyl methyl ether (2 X 10 mL). Combine the organic extracts, dry over anhydrous magnesium sulfate, filter and

49

concentrate under vacuum. Purify the residue by flash chromatography (silica gel, 2.5 g, 1.7 X 2.5 cm column, 50% ethyl acetate/hexane, 150 mL) to provide the title compound
5 (80 mg, 93% yield), $[\alpha]_D^{20} = +9.9^\circ$, ($c = 0.98$, chloroform).

Example 14

Preparation of (-)-cis-4-tert-butyloxy-cyclopent-2-enol (A)
and (-)-acetic acid cis-4-tert-butyloxy-cyclopent-2-enyl
10 ester (B).



Scheme II, step A; Cis-4-tert-butyloxy-cyclopent-2-enol (485 mg, 3.1 mmol, prepared in example 9) is dissolved in tert-butyl methyl ether (8.6 mL, anhydrous). To the
20 solution is added triethylamine (0.7 eq), pancreatin (3 wt eq, available from Sigma Chemical Company), and vinyl acetate (5 eq). The reaction is allowed to stir for 17 hours at room temperature. The reaction is then filtered through diatomaceous earth and the filtrate is concentrated
25 under vacuum. The products are separated by chromatography on silica gel (10% to 20% ethyl acetate/hexane) to provide (-)-acetic acid cis-4-tert-butyloxy-cyclopent-2-enyl ester (B, 50% yield, 76% ee), $[\alpha]_D = -10.9^\circ$, ($c = 0.98$, chloroform), ^1H NMR (CDCl_3) δ 5.94 (d, 1H, $J=5.5$ Hz), 5.89 (d, 1H, $J=5.5$ Hz), 5.46 (appt, 1H, $J=5.5$ Hz), 4.52 (appt, 1H, $J=5.5$ Hz), 2.8 (m, 1H), 2.0 (s, 3H), 1.6 (d appt, 1H, $J=4.8, 14$ Hz), 1.22 (s, 9H); ^{13}C NMR (CDCl_3) δ 171.2, 138.6, 131.6, 77.4, 77.2, 41, 28.7, 28.6, 21.4; IR (neat) ν_{max} 2976, 1738, 1364, 1242, 1196, 1067, 1020 cm^{-1} ; CIMS m/e (% relative intensity) 199 ($\text{M}+\text{H}^+$, 4), 139 ($\text{M}+\text{H}^+-\text{AcOH}$, 70), 83 (100), and (-)-cis-4-tert-butyloxy-cyclopent-2-enol (A, 194
35 mg, 40% yield, >98% ee), $[\alpha]_D = -17.2^\circ$, ($c = 1.09$, chloroform) as a yellow oil.

50

(-)-cis-4-tert-butyloxy-cyclopent-2-enolAnal. Calcd for $C_9H_{16}O_2$: C, 69.19; H, 10.32.

5 Found: C, 69.07; H, 10.37.


(-)-acetic acid cis-4-tert-butyloxy-cyclopent-2-enyl esterAnal. Calcd for $C_{11}H_{18}O_3$: C, 66.64; H, 9.15.

Found: C, 67.11; H, 9.03.

10

Example 15Preparation of (+)-cis-4-tert-butyloxy-cyclopent-2-enol.

15



20

Scheme II, step B; Dissolve (-)-acetic acid cis-4-tert-butyloxy-cyclopent-2-enyl ester (90 mg, 0.45 mmol, prepared in example 14) in THF/methanol/water (1.5/0.5/0.5 mL). Add lithium hydroxide monohydrate (23.7 mg) with stirring. After stirring for about 2 hours at room temperature, dilute the reaction with water (10 mL) and extract with tert-butyl methyl ether. Combine the organic phases, dry over anhydrous magnesium sulfate, filter and concentrate under vacuum. Purify the residue by flash chromatography (silica gel, 2g, 40% diethyl ether/hexane, 1.5 X 2.5 cm column) to provide the title compound (71 mg, quantitative yield, 76% ee) as a pale yellow oil, $[\alpha]_D^{20} = +14.6^\circ$, ($c = 1.03$, chloroform).


30

35

⁵¹
Example 16

Preparation of cis-4-benzyloxy-cyclopent-2-enol

5



10

Scheme I, step b; In a manner analogous to the procedure described in example 8, 4-benzyloxy-2-cyclopent-2-enone is prepared from 4-hydroxy-2-cyclopentenone, benzyl trichloroacetimidate and boron trifluoride diethyl etherate.

15

Scheme I, step c; A solution of lithium aluminum hydride (45 mg, 1.2 mmol) and lithium iodide (451 mg, 3.37 mmol) in diethyl ether (4 mL) is cooled to -30°C and treated dropwise over 5 minutes with a solution of 4-benzyloxy-2-cyclopent-2-enone (444 mg, 2.36 mmol, prepared above) in diethyl ether (1 mL). The reaction mixture is stirred for 1.5 hours at -25°C and then treated with 1 N sodium hydroxide (1 mL). The reaction mixture is then allowed to warm to room temperature and is filtered. The filtrate is extracted with ethyl acetate (2 X 10 mL). The organic phase is dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum. The residue is purified by chromatography to provide the title compound (151 mg, 34% yield) as a pale yellow oil, 28/4/3, cis/trans/1,4 + 1,2; ¹H NMR (CDCl₃) δ 7.3 (m, 5H), 6.05 (appt, 2H, J=7 Hz), 4.6 (m, 1H), 4.56 (dd, 2H, J=11.7, 17 Hz), 4.44 (dd, 1H, J=4, 6.8 Hz), 2.7 (m, 1H), 1.67 (d appt, 1H, J=4, 14 Hz); ¹³C NMR (CDCl₃) δ 138.6, 137.4, 134.5, 128.7, 128.1, 127.9, 81.7, 75.3, 71.3, 41.3; IR (neat) ν_{max} 3381, 2918, 2851, 1360, 1072, 1051, 1028 cm⁻¹; CIMS m/e (% relative intensity) 173 (M+H⁺-H₂O), 91 (100).

35


Anal. Calcd for C₁₂H₁₄O₂: C, 75.77; H, 7.41.
Found: C, 75.61; H, 7.78.

52

Example 17

Preparation of (-)-cis-4-benzyloxy-cyclopent-2-enol (A) and
 5 (-)-acetic acid cis-4-benzyloxy-cyclopent-2-enyl ester (B).

10



Scheme II, step A; Cis-4-benzyloxy-cyclopent-2-enol
 (500 mg, prepared in example 16) is dissolved in tert-
 butyl methyl ether (8.6 mL, anhydrous). To the solution is
 15 added triethylamine (0.7 eq), pancreatin (3 wt eq,
 available from Sigma Chemical Company), and vinyl acetate
 (5 eq). The reaction is allowed to stir for 7 hours at
 room temperature. The reaction is then filtered through
 diatomaceous earth and the filtrate is concentrated under
 20 vacuum. The products are separated by chromatography on
 silica gel (20% ethyl acetate/hexane) to provide (-)-cis-4-
 benzyloxy-cyclopent-2-enol (A) (147 mg, 29% yield) $[\alpha]_D^{20} =$
 -12° , (c = 1.09, chloroform), and (-)-acetic acid cis-4-
 benzyloxy-cyclopent-2-enyl ester (B) (427 mg, 70%
 25 yield), $[\alpha]_D^{20} = -5.2^\circ$, (c = 0.97, chloroform), ^1H NMR
 (CDCl_3) δ 7.3 (m, 5H), 6.13 (d, 1H, J=5 Hz), 5.99 (d, 1H,
 J=5 Hz), 5.5 (m, 1H), 4.59 (d, 1H, J=11.8 Hz), 4.54 (d, 1H,
 J=11.8 Hz), 4.5 (m, 1H), 2.78 (d appt, 1H, J=7.2, 14.3 Hz),
 2.05 (s, 3H), 1.76 (d appt, 1H, J=4.4, 14.3 Hz); ^{13}C NMR
 30 (CDCl_3) δ 171.1, 138.5, 136.4, 133.1, 128.7, 128, 127.9,
 81.4, 77.1, 71.2, 37.8, 21.4.

35

⁵³
Example 18

Preparation of (+)-cis-4-benzyloxy-cyclopent-2-enol.



Scheme II, step B; Dissolve (-)-acetic acid cis-4-benzyloxy-cyclopent-2-enyl ester (158 mg, 0.68 mmol, prepared in example 17) in THF/methanol/water (1.5/0.5/0.5 mL). Add lithium hydroxide monohydrate (0.75 mmol) with stirring. After stirring for about 2 hours at room temperature, dilute the reaction with water (10 mL) and extract with tert-butyl methyl ether. Combine the organic phases, dry over anhydrous magnesium sulfate, filter and concentrate under vacuum. Purify the residue by flash chromatography (silica gel, 2g, 20% ethyl acetate/hexane, 1.5 X 2.5 cm column) to provide the title compound (120 mg, 92% yield), $[\alpha]^{20}_D = +5.0^\circ$, (c = 0.93, chloroform).

10

15

20

Example 19

Preparation of (-)-cis-4-acetoxy-cyclopent-2-enol.



Scheme II, step B; Dissolve (-)-acetic acid cis-4-tert-butyldimethylsilyloxy-cyclopent-2-enyl ester (11.53 g, 45 mmol, prepared in example 10) in tetrahydrofuran (49.5 mL) and triethylamine (0.7 mL). Treat the solution with a solution of tetra-n-butylammonium fluoride (49.5 mL of a 1M solution in THF, 49.5 mmol) and stir for 2 hours at room temperature. Then concentrate the reaction under vacuum and purify the residue by chromatography (silica gel, 33% to 50% ethyl acetate/hexane) to provide a white solid (5.85 g) which is recrystallized from tert-butyl methyl ether/heptane (80 mL/ 100 mL) to provide the title compound

30


35

54

(4.99 g, 78% yield, >98% ee), $[\alpha]_D^{20} = -68^\circ$, (c = 0.98, chloroform), mp 48-49°C; ^1H NMR (CDCl_3) δ 6.12-6.14 (m, 1H), 5.99-6.01 (m, 1H), 5.49-5.54 (m, 1H), 4.70-4.77 (m, 1H), 2.83 (dt, 1H, J=14.5, 7.3 Hz), 2.22 (d, 1H, J=7.8 Hz), 2.08 (s, 3H), 1.6 (dt, 1H, J=14.5, 3.8 Hz).

Example 20

Preparation of (+)-acetic acid cis-4-tert-butyl
dimethylsilyloxy-cyclopent-2-enyl ester.



15

Dissolve (-)-cis-4-tert-butyl dimethylsilyloxy-2-cyclopentenol (1 g, 4.67 mmol, prepared in example 10) in pyridine (20 mL) and treat with acetic anhydride (2 mL). Stir the reaction overnight. Dilute the reaction with diethyl ether (100 mL), wash with 3 M hydrochloric acid (3 X 100 mL), saturated sodium bicarbonate (100 mL), brine (100 mL), dry over anhydrous magnesium sulfate, filter and concentrate under vacuum to provide the title compound (1 g, 98% yield), $R_f = 0.5$ (5% ethyl acetate/hexane), $[\alpha]_D^{20} = +1.3^\circ$, (c = 1.00, chloroform), ^1H NMR (CDCl_3) δ 5.9 (m, 1H), 5.5 (m, 1H), 4.7 (m, 1H), 2.8 (m, 1H), 2.05 (s, 3H), 1.6 (m, 1H), 0.91 (s, 9H), 0.09 (s, 6H); ^{13}C NMR (CDCl_3) δ 170.8, 138.8, 131.1, 76.9, 74.8, 41.1, 25.8, 21.1, 18.1, -4.7, -4.6; IR (neat) ν_{max} 2955, 2932, 2859, 1739, 1369, 1240, 1105, 1062, 1049 cm^{-1} ; CIMS m/e (% relative intensity) 256 ($\text{M}+\text{H}^+$, 7), 197 ($\text{M}+\text{H}^+-\text{AcOH}$, 100).

30


Anal. Calcd for $\text{C}_{13}\text{H}_{24}\text{O}_3\text{Si}$; C, 60.90; H, 9.43.
 Found: C, 60.89; H, 9.67.

35

⁵⁵
Example 21

Preparation of (+)-acetic acid cis-4-(tetrahydro-pyran-2-yloxy)-cyclopent-2-enyl ester (B).

5



10

Dissolve (-)-cis-4-(tetrahydro-pyran-2-yloxy)-cyclopent-2-enol (292 mg, 1.59 mmol, prepared in example 11) in pyridine (2.8 mL) and treat with acetic anhydride (0.39 mL) and dimethylaminopyridine (16 mg). Stir the reaction overnight. Concentrate the reaction under vacuum, dissolve the residue with ethyl acetate (10 mL). Wash with 0.5 M hydrochloric acid that is 1/2 saturated with brine (2 X 10 mL), saturated sodium bicarbonate (10 mL), brine (10 mL), dry over anhydrous magnesium sulfate, filter and concentrate under vacuum. Purify the residue by chromatography (silica gel, 10 g, 1.5 X 4 cm column, 20% ethyl acetate/hexane) to provide the title compound (290 mg, 81%).

25


30

35

⁵⁶
Example 22

Preparation of (-)-cis-4-acetoxy-cyclopent-2-enol.

5




10 Dissolve (-)-acetic acid cis-4-(tetrahydro-pyran-2-yloxy)-cyclopent-2-enyl ester (192 mg, 0.85 mmol, prepared in example 11) in ethanol (1.5 mL) and treat with p-toluenesulfonic acid (11.7 mg). Stir the reaction at room temperature for 2 hours. Add carbonate or bicarbonate to neutralize the reaction mixture and concentrate under vacuum. Purify the residue by chromatography (silica gel, 3 g, 1.5 X 3 cm column, 33% ethyl acetate/hexane, 80 mL), to provide the title compound (90 mg, 75% yield, 91% ee), $[\alpha]^{20}_D = -66.1^\circ$, (c = 0.63, chloroform).

20

Example 23

Preparation of (-)-cis-3-acetoxy-cyclopentanol.

25




30 Dissolve (-)-cis-4-acetoxy-cyclopent-2-enol (11.0 g, 77.4 mmol, prepared in example 19) in ethanol (50 mL) and treat with Raney nickel (1.1 g, previously washed with water (2 X 50 mL) and ethanol (2 X 50 mL), Ra-Ni). Charge the atmosphere with hydrogen at 50 psi (344.74 kPa) and shake the mixture. After 20 minutes, filter the solution and treat the filtrate with triethylamine (1.0 mL, 7.2 mmol). After one hour concentrate the solution under vacuum and distill the residue by Kugelrohr distillation (60-80°C, 1mm Hg), to provide the title compound (9.74 g, 87%) as a colorless oil.

35

⁵⁷
Example 24

Preparation of (1S,3R)-acetic acid 3-methanesulfonyloxy-
cyclopentyl ester.

5



10 Dissolve (1S,3R)-cis-3-acetoxycyclopentanol (9.75 g, 67.6 mmol, prepared in example 23) in tert-butyl methyl ether (80 mL, anhydrous) and cool to -8°C with stirring. Add methanesulfonyl chloride (5.7 mL, 73.6 mmol, mesyl chloride) over 5 minutes, followed by dropwise addition of

15 triethylamine (11.4 mL, 81.2 mL), over about 30 minutes, maintaining the temperature below -2°C. The ice bath is then removed and the mixture is stirred for 2 hours. The mixture is poured into a water/brine mixture (50 mL/50 mL). The layers are separated and the aqueous layer extracted

20 with tert-butyl methyl ether (100 mL). The organic layer and extract is combined, dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum to provide the title compound (14.4 g) as a yellow oil; ¹H NMR (CDCl₃)

25 δ 5.1 (m, 2H), 3.02 (s, 3H), 2.41 (m, 1H), 2.05 (s, 3H), 2.0 (m, 5H).


30

35

58
Example 25

Preparation of (-)-cis-3-tert-butyldimethylsilyloxy-
cyclopentanol.

5



10 Dissolve (-)-cis-4-tert-butyldimethylsilyloxy-2-cyclopentenol (28.85 g, 135 mmol, prepared in example 10) in ethanol (75 mL) and treated with Raney nickel (1.85 g, 32 mmol, previously washed with water (2 X 50 mL) and ethanol (2 X 50 mL)). Charge the atmosphere with hydrogen at 50 psi (344.74 kPa) and shake the mixture. After 5.25
15 hours, filter the reaction. Cool the filtrate to 0°C and treat with sodium borohydride (0.54 g, 14.3 mmol). After stirring for 2 hours, concentrate the solution under vacuum and distill the resulting oil by Kugelrohr distillation
20 (40-60°C, 1 mmHg) to provide the title compound (25.5 g, 87%) as a colorless oil, $[\alpha]_D^{20} = -3.9^\circ$, ($c = 0.99$, chloroform); ^1H NMR (CDCl_3) δ 4.4 (m, 1H), 4.3 (m, 1H), 3.03 (d, 1H, $J=10.5$ Hz), 1.9-1.6 (m, 6H), 0.89 (s, 9H), 0.07 (s, 6H); ^{13}C NMR (CDCl_3) δ 74.9, 74.1, 44.4, 34.2, 34.1, 25.8, 17.9, -4.9, -5.0; IR (neat) ν_{max} 3405, 2957, 2932, 2888, 2858, 1256, 1091, 1069, 1038, 1026 cm^{-1} ; CIMS m/e (% relative intensity) 217 ($\text{M}+\text{H}^+$, 81), 199 ($\text{M}+\text{H}^+-\text{H}_2\text{O}$, 37), 67 (100). This (-)-enantiomer (title compound) could not be
25 separated from the (+)-enantiomer (antipode) using the
30 previously described chiral column.


Anal. Calcd for $\text{C}_{11}\text{H}_{24}\text{O}_2\text{Si}$: C, 61.06; H, 11.17.
Found: C, 61.28; H, 10.85.

35 The above reductions in examples 23 and 25 may also be effected using such catalysts as platinum on Al_2O_3 , nickel boride, platinum on CaCO_3 , Wilkinson's Catalyst ($[(\text{C}_6\text{H}_5)_3\text{P}]_3\text{RhCl}$) and the like.

⁵⁹
Example 26

Preparation of (1S,3R)-methanesulfonic acid 3-tert-butyl-
dimethylsilyloxy-cyclopentyl ester.

5



10 Dissolve (-)-cis-3-tert-butyl-
cyclopentanol (9.20 g, 42.5 mmol) in anhydrous tert-butyl
methyl ether (50 mL) and cool to -5°C. Treat the solution
with methanesulfonyl chloride (3.6 g, 46.5 mmol, mesyl
chloride), followed by triethylamine (7.2 mL, 51.7 mmol),
15 at such a rate as to keep the temperature between -5°C and
-2°C with an ice bath. The ice bath is removed and the
solution is stirred for 2 hours. The mixture is then
transferred to a separatory funnel and treated with
brine/water (50 mL/50 mL). The layers are separated and
20 the aqueous layer is extracted with tert-butyl methyl ether
(2 X 50 mL). The organic layer and extracts are combined,
washed with brine, dried over anhydrous magnesium sulfate,
filtered and concentrated under vacuum to provide the title
compound (12.1 g, 97% yield) as a colorless oil; ¹H NMR
25 (CDCl₃) δ 5.1 (m, 1H), 4.2 (m, 1H), 2.99 (s, 3H), 2.3 (m,
1H), 2.0 (m, 3H), 1.8 (m, 2H), 0.88 (s, 9H), 0.05 (s, 6H).


30

35

60

Example 27Preparation of 4-trityloxy-2-cyclopentenone.

5



10 Scheme I, step b; A solution of trityl chloride (3.44 g, 12.3 mmol) in methylene chloride (20 mL) is treated sequentially with 1,8-diazabicyclo[5.4.0]undec-7-ene (2.2 mL, 14.7 mmol, DBU) and 4-hydroxy-2-cyclopentenone (1.01 g, 10.0 mmol, in 5 mL of methylene chloride, prepared in
15 example 1). The reaction is stirred for 3 days at room temperature and then poured onto ice (approximately 25 mL). The phases are separated and the organic phase is washed with water (25 mL). The organic phase is dried over anhydrous magnesium sulfate, filtered and concentrated
20 under vacuum. The residue is purified by column chromatography (silica gel, 10-20% ethyl acetate/hexane) to provide the title compound (1.26 g, 36 %) as a pale yellow oil; ^1H NMR (CDCl_3) δ 7.5 (m, 6H), 7.3 (m, 9H), 6.85 (dd, 1H), 6.05 (d, 1H), 4.8 (m, 1H), 2.1 (m, 2H); ^{13}C NMR (CDCl_3)
25 δ 206.6, 162.9, 144.3, 135.2, 128.8, 128.4, 127.7, 88.2, 73.1, 43.4; IR (KBr) ν_{max} 3061, 1719, 1491, 1449, 1352, 1181, 1107, 1053 cm^{-1} .


30

35

⁶¹
Example 28

Preparation of (+/-)-cis-4-trityloxy-2-cyclopentenol.

5



10 Scheme I, step C; A slurry of 4-trityloxy-2-cyclopentenone (1.03 g, 3.03 mmol, prepared in example 27) in toluene (8 mL) is cooled to -20°C and treated sequentially with lithium aluminum hydride (76 mg, 2.0 mL), lithium iodide (1.06 g, 7.9 mmol) and dropwise with tert-

15 butyl methyl ether (2 mL, over 5 minutes). The reaction is stirred for 1 hour at -20°C, warmed to 0°C over 30 minutes, and stirred at 0°C to 15°C for 4 hours. The reaction is quenched by slow addition of 1N NaOH (2 mL) and then the reaction is filtered. The solids are washed with tert-butyl

20 methyl ether and the phases of the filtrate are separated. The organic phase is dried over anhydrous magnesium sulfate, filtered and concentrated under vacuum. The residue is purified by column chromatography (silica gel, 20% ethyl acetate/hexane) to provide the title compound as


25 a white foam (980 mg, 95%). ¹H NMR (CDCl₃) δ 7.5 (m, 6H), 7.3 (m, 9H), 5.79 (d, 1H), 5.14 (d, 1H), 4.5 (m, 1H), 4.4 (m, 1H), 2.2 (m, 1H), 1.42 (d, 1H); ¹³C NMR (CDCl₃) δ 145.1, 136.2, 135.9, 129.0, 128.1, 127.3, 87.7, 77.4, 74.9, 43.2; IR (KBr) ν_{max} 3422, 3057, 1491, 1364, 1084, 1065, 1024

30 cm⁻¹.

62

Example 28aPreparation of cis-2-cyclopentenyl-1,4-diol.

5




A solution of (+/-)-cis-4-trityloxy-2-cyclopentenol
10 (200 mg, 0.58 mmol, prepared in example 28) in ethanol (2
mL) is treated with p-toluenesulfonic acid (20 mg) and
stirred at 55°C for 8 hours. The reaction mixture is then
concentrated under vacuum (55°C/15 mmHg) and the residue is
purified by column chromatography (silica gel, 10%
15 acetone/ethyl acetate) to provide the title compound (58
mg); cis/trans/1-2 + 1-4 addition, 30/1/trace.

Example 29

20 Preparation of (+/-)-cis-3-tert-
butyldimethylsilyloxy-cyclopentanol.


25



Combine (+/-)-cis-4-tert-butyldimethylsilyloxy-2-
cyclopentenol (2.50 g, 11.6 mmol, prepared in example 3)
and Ni₂B (8.5 mL of a 0.14 M slurry in methanol, 10 mol%) in
30 methanol (14 mL). Stir the slurry under an atmosphere of
hydrogen for 18.5 hours. Then replace the hydrogen
atmosphere with nitrogen, filter through diatomaceous earth
and rinse the solids with methanol (50 mL). Concentrate
the filtrate under vacuum (15 mmHg/40°C) and purify the
35 residue by Kugelrohr distillation (0.6 mmHg/60-65°C) to
provide the title compound as a colorless oil (2.31 g,
92%).

63
Example 30

Preparation of (1S,3R)-(-)-cis-3-tert-
butyldimethylsilyloxycyclopentanol (A) and (1R,3S)-(+)-cis-
 5 3-tert-butyldimethylsilyloxycyclopentanyl acetate (B).



Scheme III, step A; Combine (+/-)-cis-3-tert-
 butyldimethylsilyloxycyclopentanol (2.119 g, 9.8 mmol,
 prepared in example 29), pancreatin (6.2 g, 3 weight
 15 equivalents), triethylamine (0.9 mL, 6.5 mmol) and vinyl
 acetate (4.3 mL) in tert-butyl methyl ether (12 mL) and
 stir for 27 hours at room temperature. Then filter the
 reaction through diatomaceous earth and concentrate the
 filtrate under vacuum (room temperature/ 15 mmHg). Purify
 20 the residue by column chromatography [silica gel, 55 g,
 hexane (300 mL) followed by 5% ethyl acetate/hexane (500
 mL)] to provide the (1R,3S)-(+)-3-tert-
 butyldimethylsilyloxycyclopentanyl acetate (1.23 g, 49%
 yield, 98% ee as determined from gas chromatography with a
 25 chiral column) and (1S,3R)-(-)-3-tert-
 butyldimethylsilyloxycyclopentanol (771 mg, 37% yield, 92%
 ee as determined from its acetate derivative followed by GC
 chiral column analysis, see example 30a).

30 Physical data for (1S,3R)-(-)-3-tert-
butyldimethylsilyloxycyclopentanol; $[\alpha]_D^{20} = -3.7^\circ$ (c =
 1.20, chloroform); ^1H NMR (CDCl_3) δ 4.4 (m, 1H), 4.3 (m,
 1H), 3.03 (d, 1H), 1.9-1.6 (m, 6H), 0.89 (s, 9H), 0.07 (s,
 6H); ^{13}C NMR (CDCl_3) δ 74.9, 74.1, 44.4, 34.2, 34.1, 25.8,
 17.9, -4.9, -5.0; IR (neat) ν_{max} 3405, 2957, 2932, 2888,
 35 2858, 1256, 1091, 1069, 1038, 1026 cm^{-1} .

Anal. calcd for $\text{C}_{11}\text{H}_{24}\text{O}_2\text{Si}$: C, 61.06; H, 11.18.

64

Found: C, 61.32; H, 11.13.

Physical data for (1R,3S)-(+)-3-tert-
5 butyldimethylsilyloxycyclopentanyl acetate; $[\alpha]^{20}_D = +7.0^\circ$
(c = 1.12, chloroform).

Anal. calcd for $C_{13}H_{26}O_3Si$: C, 60.42; H, 10.14.

Found: C, 60.70; H, 10.51.

10

15

20

25


30

35

65

Example 30a

Preparation of (1S,3R)-(-)-cis-3-tert-butyl-3-dimethylsilyloxycyclopentanyl acetate.




Combine (1S,3R)-(-)-cis-3-tert-butyl-3-dimethylsilyloxycyclopentanol (209 mg, 2.5 mmol, prepared in example 30), pyridine (1 mL), acetic anhydride (0.1 mL) and DMAP (5 mg). Stir the reaction at room temperature for 15.5 hours. Then dilute the reaction with diethyl ether (10 mL) and wash sequentially with 0.5 M HCl 1/2 saturated with sodium chloride (2 X 10 mL), saturated sodium bicarbonate (10 mL) and brine (10 mL). Analysis of the filtrate indicates 92% ee for the title compound. Dry the organic phase over anhydrous magnesium sulfate, filter and concentrate under vacuum.

$[\alpha]_D^{20} = -6.6^\circ$ ($c = 0.99$, chloroform); ^1H NMR (CDCl_3) δ 5.0 (m, 1H), 4.2 (m, 1H), 2.2 (m, 1H), 2.02 (s, 3H), 1.9 (m, 1H), 1.7 (m, 2H), 0.89 (s, 9H), 0.05 (s, 3H), 0.04 (s, 3H); ^{13}C NMR (CDCl_3) δ 171.3, 75.0, 72.7, 42.3, 34.3, 30.5, 26.0, 21.5, 18.3, -4.5; IR (neat) ν_{max} 2957, 2932, 2859, 1740, 1250, 1115, 1096, 1045 cm^{-1} .

66

WHAT IS CLAIMED IS:

1. A process for preparing a CIS compound of the
5 formula



formula (II)

- 10 wherein Pg is selected from the group consisting of benzyl, substituted benzyl, $-\text{CH}_2\text{OCH}_3$, $-\text{CH}_2\text{SCH}_3$, $-\text{OCH}_2\text{OCH}_2\text{phenyl}$, $-\text{CH}_2\text{OCH}_2\text{CH}_2\text{OCH}_3$, $-\text{CH}_2\text{OCH}_2\text{CCl}_3$, $-\text{CH}(\text{OCH}_2\text{CH}_2\text{Cl})_2$, $-\text{CH}_2\text{OCH}_2\text{CH}_2\text{Si}(\text{CH}_3)_3$, $-\text{CH}(\text{OC}_2\text{H}_5)\text{CH}_3$, $-\text{C}(\text{OCH}_3)(\text{CH}_3)_2$,
15 $-\text{CH}(\text{CH}_3)\text{OCH}(\text{CH}_3)_2$, $-\text{CH}_2\text{CCl}_3$, $-\text{C}(\text{CH}_3)_3$, $-\text{CH}_2\text{CH}=\text{CH}_2$, $-\text{CH}_2\text{CH}=\text{CHphenyl}$, $-\text{CH}(\text{phenyl})_2$, $-\text{C}(\text{phenyl})_3$, tetrahydropyranyl, 4-methoxytetrahydropyranyl, 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl, tetrahydrofuranyl,
20 tetrahydrothiofuranyl, and $\text{SiR}_1\text{R}_2\text{R}_3$, wherein R_1 , R_2 and R_3 are each independently C_1 - C_4 alkyl, phenyl, benzyl, substituted phenyl or substituted benzyl, comprising;
a) dissolving a compound of the formula



formula (I)

- 25 wherein Pg is defined as above, in a suitable organic solvent; and
30 b) treating the solution with a suitable Lewis acid and a suitable reducing agent at a temperature of from about -100°C to about 20°C .

- 35 2. A process according to claim 1 wherein the suitable reducing agent is lithium aluminum hydride.

3. A process according to claim 2 wherein the suitable organic solvent is toluene/diethyl ether.

67

4. A process according to claim 2 wherein the suitable organic solvent is diethyl ether.

5

5. A process according to claim 2 wherein the suitable organic solvent is toluene/tert-butyl methyl ether.

6. A process as in either claim 2, claim 3 or claim 4 wherein the suitable Lewis acid is lithium iodide.

7. A process according to claim 6 wherein the mixture is cooled to a temperature of from about -78°C to about -10°C.


15

8. A process according to claim 6 wherein the mixture is cooled to a temperature of about -25°C.

9. A process according to claim 8 wherein Pg is tert-butyl dimethylsilyl.

10. A process for the preparation of the CIS enantiomer of the formula:

25



formula (IIa)


wherein Pg is selected from the group consisting of benzyl, substituted benzyl, -CH₂OCH₃, -CH₂SCH₃, -CH₂OCH₂phenyl, -CH₂OCH₂CH₂OCH₃, -CH₂OCH₂CCl₃, -CH(OCH₂CH₂Cl)₂, -CH₂OCH₂CH₂Si(CH₃)₃, -CH(OC₂H₅)CH₃, -C(OCH₃)(CH₃)₂, -CH(CH₃)OCH(CH₃)₂, -CH₂CCl₃, -C(CH₃)₃, -CH₂CH=CH₂, -CH₂CH=CHphenyl, -CH(phenyl)₂, -C(phenyl)₃, tetrahydropyranyl, 4-methoxytetrahydropyranyl, 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl, tetrahydrofuranyl, tetrahydrothiofuranyl, and SiR₁R₂R₃, wherein R₁, R₂ and R₃

68

are each independently C₁-C₄ alkyl, phenyl, benzyl, substituted phenyl or substituted benzyl, comprising;

a) dissolving an enantiomeric compound of the formula;

5



formula (Ia)


10 wherein Pg is defined as above, in a suitable organic solvent; and

b) treating the solution with a suitable Lewis acid and a suitable reducing agent at a temperature of from about -100°C to about 20°C.

15

11. A process for the preparation of the CIS enantiomer of the formula:

20



formula (IIb)

wherein Pg is selected from the group consisting of benzyl, substituted benzyl, -CH₂OCH₃, -CH₂SCH₃, -CH₂OCH₂phenyl,

25


-CH₂OCH₂CH₂OCH₃, -CH₂OCH₂CCl₃, -CH(OCH₂CH₂Cl)₂,
-CH₂OCH₂CH₂Si(CH₃)₃, -CH(OC₂H₅)CH₃, -C(OCH₃)(CH₃)₂,
-CH(CH₃)OCH(CH₃)₂, -CH₂CCl₃, -C(CH₃)₃, -CH₂CH=CH₂,
-CH₂CH=CHphenyl, -CH(phenyl)₂, -C(phenyl)₃,

30

tetrahydropyranyl, 4-methoxytetrahydropyranyl, 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl, tetrahydrofuranyl, tetrahydrothiofuranyl, and SiR₁R₂R₃, wherein R₁, R₂ and R₃ are each independently C₁-C₄ alkyl, phenyl, benzyl, substituted phenyl or substituted benzyl, comprising;

35

a) dissolving an enantiomeric compound of the formula; wherein Pg is defined as above, in a suitable organic solvent; and




formula (Ib)

5

b) treating the solution with a suitable Lewis acid and a suitable reducing agent at a temperature of from about -100°C to about 20°C .


10

12. A process for the preparation of the CIS compounds of the formulas (IIb) and (IV):



formula (IIb)

15



formula (IV)

20


wherein Z is $\text{C}_2\text{-C}_4$ alkanoyl; and Pg is selected from the group consisting of benzyl, substituted benzyl, $-\text{CH}_2\text{OCH}_3$, $-\text{CH}_2\text{SCH}_3$, $-\text{CH}_2\text{OCH}_2\text{phenyl}$, $-\text{CH}_2\text{OCH}_2\text{CH}_2\text{OCH}_3$, $-\text{CH}_2\text{OCH}_2\text{CCl}_3$, $-\text{CH}(\text{OCH}_2\text{CH}_2\text{Cl})_2$, $-\text{CH}_2\text{OCH}_2\text{CH}_2\text{Si}(\text{CH}_3)_3$, $-\text{CH}(\text{OC}_2\text{H}_5)\text{CH}_3$, $-\text{C}(\text{OCH}_3)(\text{CH}_3)_2$, $-\text{CH}(\text{CH}_3)\text{OCH}(\text{CH}_3)_2$, $-\text{CH}_2\text{CCl}_3$, $-\text{C}(\text{CH}_3)_3$, $-\text{CH}_2\text{CH}=\text{CH}_2$, $-\text{CH}_2\text{CH}=\text{CHphenyl}$, $-\text{CH}(\text{phenyl})_2$, tetrahydropyranyl, 4-methoxytetrahydropyranyl, 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl, tetrahydrofuranyl, tetrahydrothiofuranyl, and $\text{SiR}_1\text{R}_2\text{R}_3$, wherein R_1 , R_2 and R_3 are each independently $\text{C}_1\text{-C}_4$ alkyl, phenyl, benzyl, substituted phenyl or substituted benzyl, comprising:

a) dissolving a compound of the formula (I) wherein Pg is defined as above, in a suitable organic solvent;

25

30

35




formula (I)

5

b) treating the solution with a suitable Lewis acid and a suitable reducing agent at a temperature of from about -100°C to about 20°C to yield the CIS compound of formula (II);

10



formula (II)

15

wherein Pg is as defined above;

c) treating the CIS compound of formula (II) with a suitable enzyme and an excess of a suitable acylating agent in a suitable solvent, to yield a mixture of compounds of the formulas (IIb) and (IV), as defined above; and

20

d) separating the compound of formula (IIb) from the compound of formula (IV).

13. A process according to claim 12 wherein the suitable acylating agent is vinyl acetate.

25

14. A process according to claim 13 wherein the suitable enzyme is pancreatin.


15. A process according to claim 14 wherein the suitable solvent is tert-butyl methyl ether.

30


16. A process according to claim 14 wherein the suitable solvent is cyclohexane.

35

17. A process according to claim 12 for preparing compounds of formula, further comprising, hydrolyzing the compound of formula (IV)



formula (IIa)



formula (IV)


wherein Z is C₂-C₄ alkanoyl; and Pg is selected from the group consisting of benzyl, substituted benzyl, -CH₂OCH₃, -CH₂SCH₃, -CH₂OCH₂phenyl, -CH₂OCH₂CH₂OCH₃, -CH₂OCH₂CCl₃, -CH(OCH₂CH₂Cl)₂, -CH₂OCH₂CH₂Si(CH₃)₃, -CH(OC₂H₅)CH₃, -C(OCH₃)(CH₃)₂, -CH(CH₃)OCH(CH₃)₂, CH₂CCl₃, -C(CH₃)₃, -CH₂CH=CH₂, -CH₂CH=CHphenyl, -CH(phenyl)₂, -C(phenyl)₃, tetrahydropyranyl, 4-methoxytetrahydropyranyl, 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl, tetrahydrofuranyl, tetrahydrothiofuranyl, and SiR₁R₂R₃, wherein R₁, R₂ and R₃ are each independently C₁-C₄ alkyl, phenyl, benzyl, substituted phenyl or substituted benzyl.

18. A process according to claims 1, 10, 11, 12 or 17 wherein a suitable alcohol is added to the reaction mixture concomitantly with or prior to treating the compound of formulas (I), (Ia) or (Ib) with the suitable reducing agent.

19. A process according to claim 18 wherein the suitable alcohol is tert-butyldimethylsilanol.


20. A process according to claim 18 wherein the suitable alcohol is isopropanol.

21. A process for the preparation of the CIS compounds of the formulas (VIb) and (VII):



formula (VIb)


5



formula (VII)

10

wherein Z is C₂-C₄ alkanoyl; and Pg is selected from the group consisting of benzyl, substituted benzyl, -CH₂OCH₃,
 15 -CH₂SCH₃, -CH₂OCH₂phenyl, -CH₂OCH₂CH₂OCH₃, -CH₂OCH₂CCl₃,
 -CH(OCH₂CH₂Cl)₂, -CH₂OCH₂CH₂Si(CH₃)₃, -CH(OC₂H₅)CH₃,
 -C(OCH₃)(CH₃)₂, -CH(CH₃)OCH(CH₃)₂, -CH₂CCl₃, -C(CH₃)₃,
 -CH₂CH=CH₂, -CH₂CH=CHphenyl, -CH(phenyl)₂,
 tetrahydropyranyl, 4-methoxytetrahydropyranyl,
 20 3-bromotetrahydropyranyl, tetrahydrothiopyranyl,
 4-methoxytetrahydrothiopyranyl, tetrahydrofuranyl,
 tetrahydrothiofuranyl, and SiR₁R₂R₃, wherein R₁, R₂ and R₃
 are each independently C₁-C₄ alkyl, phenyl, benzyl,
 substituted phenyl or substituted benzyl, comprising
 25 treating the CIS compound of formula (VI);



formula (VI)

30

wherein Pg is as defined above, with a suitable enzyme and an excess of a suitable acylating agent in a suitable solvent, to yield a mixture of compounds of the formulas (VIb) and (VII), as defined above; and

35

f) separating the compound of formula (VIb) from the compound of formula (VII).

22. A process according to claim 21 wherein the suitable acylating agent is vinyl acetate.

23. A process according to claim 22 wherein the
suitable enzyme is pancreatin.

5

24. A process according to claim 23 wherein the
suitable solvent is tert-butyl methyl ether.

10

15

20

25

30

35

INTERNATIONAL SEARCH REPORT

Intern. Appl. No.
PCT/US 96/02801

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07B53/00 C07C43/196 C07F7/18 C07C41/26 C12P41/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07B C07C C07F C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 106, no. 6, 21 March 1984, DC US, pages 1750-1759, XP002004369 M. G. ZAGORSKI ET AL: "Base-catalyzed fragmentation of 2,3-dioxabicyclo[2.2.1]heptane, the bicyclic peroxide nucleus of prostaglandin endoperoxides: large secondary deuterium kinetic isotope effects"	1-5,10, 11
Y	see p. 1751, col. 1, lines 1-6 from bottom and col. 2; p. 1756, col. 2, lines 1-16 from bottom --- -/--	12-17



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

31 May 1996

Date of mailing of the international search report

06.06.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Wright, M

INTERNATIONAL SEARCH REPORT

Intern. Application No

PCT/US 96/02801

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	HETEROCYCLES, vol. 16, no. 4, 1981, AMSTERDAM NL, pages 605-608, XP002004370 S. TAKANO ET AL: "An efficient synthesis of cis-oxabicyclo[3.3.0]oct-6-en-3-one" see schemes 1 and 2 ---	1-20
Y	LIEBIGS ANNALEN DER CHEMIE, no. 3, March 1991, WEINHEIM DE, pages 195-200, XP002004371 F. THEIL ET AL: "Investigations of the pancreatin-catalyzed acylation of cis-cyclopent-2-ene-1,4-diol with various trichloroethyl and vinyl alkanoates" cited in the application see page 195 - page 197 ---	12-17
A	TETRAHEDRON, (INCL TETRAHEDRON REPORTS), vol. 47, no. 36, 1991, OXFORD GB, pages 7569-7582, XP002004372 F. THEIL ET AL: "Lipase-catalyzed transesterification of meso-cyclopentane diols" cited in the application see page 7573 - page 7575 -----	21-24